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Abstract 
 
Metastatic melanoma, a cancer historically refractory to chemotherapeutic strategies, has 
a poor prognosis and accounts for the majority of skin cancer related mortality. Although 
the recent approval of two new drugs combating this disease, Ipilimumab and Vemurafenib 
(PLX4032), has demonstrated for the first time in decades an improvement in overall 
survival; the clinical efficacy of these drugs has been marred by severe adverse immune 
reactions and acquired drug resistance in patients, respectively. Thus, understanding the 
etiology of metastatic melanoma will contribute to the improvement of current therapeutic 
strategies while leading to the development of novel drug approaches. 
 
In order to identify recurrently mutated genes of therapeutic relevance in metastatic 
melanoma, a panel of stage III local lymph node melanomas were extensively 
characterised using high-throughput genomic technologies. This led to the identification of 
mutations in TFG in 5% of melanomas from a candidate gene sequencing approach using 
SNP array analysis, 24% of melanomas with mutations in MAP3K5 or MAP3K9 though 
unbiased whole-exome sequencing strategies, and inactivating mutations in NF1 in 
BRAF/NRAS wild type tumours though pathway analysis. Lastly, this thesis describes the 
development of a melanoma specific mutation panel that can rapidly identify clinically 
relevant mutation profiles that could guide effective treatment strategies through a 
personalised therapeutic approach.  
 
These findings are discussed in respect to a number of important issues raised by this 
study including the current limitation of next-generation sequencing technology, the 
difficulty in identifying ‘driver’ mutations critical to the development of melanoma due to 
high carcinogenic exposure by UV radiation, and the ultimate application of mutation 
screening in a personalised therapeutic setting. In summary, a number novel genes 
involved in metastatic melanoma have been identified that may have relevance for current 
therapeutic strategies in treating this disease. 
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Chapter 1- Introduction 
 
1.1. Significance of metastatic melanoma 
 
Skin cancer (non-melanoma and melanoma) is the most common form of cancer in 
Australia and represents a significant burden on the healthcare system costing 
approximately $300 million a year [1]. In 2007, there were 10,342 cases of melanoma in 
Australia, representing approximately 10% of all cancers diagnosed.  As such, Australia 
has one of the highest incidences  of skin cancer in the world [2]. Of particular concern is 
that the incidence of melanoma is increasing, which, similar to other countries including 
the United States [3], has more than doubled over the last 20 years [2]. Although all forms 
of skin cancer can seriously impact health, melanoma accounts for the majority of skin 
cancer related mortality [4]. A total of 1279 deaths due to melanoma were documented in 
Australia in 2007 [2]. 
 
Melanoma is a malignant skin cancer originating from the unregulated growth of 
melanocytes, cells responsible for pigmentation in the skin. Although a subset of 
melanomas have a familial hereditary component, the majority arise through the gradual 
accumulation of genetic abnormalities caused by carcinogenic exposure of solar ultraviolet 
(UV) radiation. It is the acquisition of somatic mutations in critical genes controlling a range 
of important cellular processes that results in the proliferation and dissemination of 
melanoma throughout the body.  
 
For melanomas that are detected early in pathogenesis, surgical removal at the primary 
site results in a 95% overall survival rate. However, due to the highly aggressive nature of 
melanoma, tumours may remain undetected without regular skin examinations until they 
have metastasized either locally to lymph nodes or distally to other organs. Upon 
metastasis, surgical excision becomes problematic and survival rates are dramatically 
reduced, with a median life expectancy of 6 months and only 5% of patients surviving 
beyond 5 years [4]. 
 
The high mortality rate of melanoma is essentially due to the lack of effective treatments, 
particularly for late stage or disseminated disease. Improvements to existing therapies or 
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the development of novel drug strategies are required in order to increase overall survival 
in patients with metastatic melanoma. 
 
1.2. Therapeutic approaches in the treatment of metastatic melanoma 
 
Until recently, treatment regimens for patients with metastatic melanoma have remained 
bleak with the availability of only a handful of approved therapies which have had minimal 
impact on overall survival. Traditional chemotherapeutic approaches fail to promote 
durable response rates, while immunological strategies, such as treatment with interleukin 
2 (IL-2) or interferon alpha (IFN-α), result in high grade toxicities limiting their use in the 
clinic [5].  
 
In 2011, for the first time in 40 years, two new drugs were approved for metastatic 
melanoma and each has demonstrated a significant improvement in overall survival. 
These drugs, Ipilimumab and Vemurafenib, have significantly altered the standard of care 
for patients with metastatic melanoma [6]. The following section describes previous and 
current strategies that have been implemented in the clinic for the treatment of metastatic 
melanoma.  
 
1.2.1. Chemotherapeutic strategies 
 
Melanoma has historically been refractive to chemotherapeutic treatments. Although a 
number of agents have been assessed in clinical trials [7], dacarbazine (DTIC), until 
recently, has been the standard approved treatment option for patients with advanced 
(stage IV) melanoma.  
 
DTIC is a cytostatic agent with alkylating properties that inhibits DNA synthesis and 
promotes growth arrest. Intravenously administered, DTIC is a pro-drug that requires 
processing within the liver to first release the active compound 5-(3-methyl-1-
triazeno)imadazole-4-carboxamide (MTIC). Although complete responses in patients are 
occasionally observed, clinical trials have demonstrated response rates in only 5-15% of 
patients, with a median durability of 6 to 12 months [8]. 
 
An orally administered pro-drug, Temozolomide (TMZ), also uses MTIC as its active 
compound, however it does not require liver processing and can be converted 
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systemically. One advantage of TMZ to DTIC is its ability to cross the blood-brain barrier, 
potentially enabling it to be efficacious for treating brain metastases. Clinical trials have 
since shown low objective response rates of brain metastases to TMZ [9], although 
evidence suggests that it may decrease the incidence of relapse [10].  Regardless of 
comparable low response rates between TMZ and DTIC [11], alternative strategies to 
standard chemotherapeutic approaches are required to improve overall rates of survival in 
patients with metastatic melanoma.  
 
1.2.2. Immunological approaches 
 
Compared to other malignancies, melanoma has long been regarded a forerunner for 
immunotherapeutic approaches in the treatment of solid cancers. The first immunological 
drugs approved for the treatment of metastatic melanoma was IFN-α and high dose IL-2 
[12, 13]. The use of these cytokines is typically associated with response rates of 10-20%, 
with approximately 5% of patients exhibiting long-term responses; in some cases, 
remission of up to 5-10 years [12, 13]. Due to the nature of these treatment regimens in 
eliciting strong immune reactions, severe adverse side effects are frequently observed. As 
such, treatment via these modalities is usually limited to those patients who are relatively 
healthy and have excellent organ capacity, but still require intensive clinical observation 
during treatment. These drugs can be used in conjunction with chemotherapeutic 
strategies, however this approach is associated with the risk of increased toxicity with 
minimal survival benefit [14].  
 
More recently, results from anti-CTLA4 antibodies designed to promote sustained T cell 
activation have led to the approval of Ipilimumab (Yervoy) in the treatment of metastatic 
melanoma. Phase III clinical trials of Ipilimumab used as a single agent or in conjunction 
with DTIC have improved rates of overall survival [15, 16]; however, response is often 
associated with initial delays in tumour regression. Despite these findings, the use of 
Ipilimumab can promote severe grade III and IV side effects leading to premature 
termination of therapy, and on rare occasions, treatment-related mortalities [16].  
 
A number of challenges regarding the clinical management of Ipilimumab remain, and 
hopefully, with the identification of positive biomarkers of drug response, improvements in 
the clinical utility of this drug will occur. Investigations into biomarkers are currently in their 
infancy, however, tumours with active immune microenvironments [17] and those 
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expressing immune-related genes [18] may indicate favourable responses in patients. 
Despite the current lack of robust biomarkers, Ipilimumab has quickly been established as 
the standard treatment for non-BRAF-mutated melanoma patients (discussed in more 
detail below).   
 
1.2.3. Molecularly based targeted therapies 
 
Aside from chemotherapeutic and immunological approaches, molecularly based targeted 
therapy is a novel drug approach that counteracts the effect of acquired mutations 
responsible for tumorigenesis.  The first of these drugs to demonstrate significant success 
in cancer was Imatinib mesylate (Gleevac); a tyrosine kinase inhibitor, originally designed 
to target an oncogene formed by a BCR-ABL translocation event observed in chronic 
myeloid leukaemia (CML). Imatinib is highly effective in CML treatment, with 76% of 
patients (n=343) showing some form of cytogenic response and 41% with complete 
remission [19].  The effectiveness of Imatinib in BCR-ABL fusion tumours provided a „proof 
of principle‟ for subsequent targeted therapeutics in other malignancies.  
 
The first forays of targeted therapies in melanoma coincided with the seminal finding of 
somatic oncogenic mutations in BRAF, a member of the serine/threonine family of protein 
kinases, occurring in 66% of melanomas [20].  Mutation of BRAF has since been more 
accurately estimated to occur in ~50% of melanomas, the majority of which are accounted 
for by a valine to glutamate substitution at coding position 600 (V600E, initially reported as 
V599E). Mutations such as V600E disrupt the inactive conformation of the kinase domain 
resulting in constitutive auto-phosphorylation and downstream signalling of the mitogen-
activated protein kinase (MAPK) pathway [21].  
 
Functional analysis of mutant BRAF showed that exogenously expressing V600E BRAF in 
mice promoted tumorigenicity [22], while conversely, suppression of mutant BRAF by 
siRNA led to cell growth arrest and apoptosis [23, 24]. The development of a small 
molecular inhibitor of tyrosine kinases, Sorafenib, and successful application in other 
malignancies, provoked testing the efficacy of such drugs in melanoma [25].  
Unfortunately, phase II and phase III clinical trials of Sorafenib in metastatic melanoma did 
not demonstrate an increase in overall survival compared to standard chemotherapeutic 
strategies [26, 27].  
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Further refinement in molecular drug design led to the development of highly selective 
inhibitors of BRAF V600E tumours [28]. One of these, Vemurafenib (also known as 
PLX4032 or Zelboraf), was the second drug to receive approval in 2011 for use in 
metastatic melanoma.  Vemurafenib results in dramatic rates of initial tumour regression, 
with patients demonstrating an increase in overall survival at 6 months compared to DTIC 
[29]. However, long-term response rates have been hindered by tumour acquired drug 
resistance frequently observed in the majority of patients. A number of mechanisms of 
tumour resistance to Vemurafenib have been identified [30-34], and it is hoped that 
through application of this knowledge, together with continued research, long-term 
response rates and overall survival will be improved (Figure 1.1).  
 
Interestingly, the use of Vemurafenib frequently results in the development of skin lesions, 
such as squamous cell carcinomas, in patients undergoing therapy [35]. Although not life-
threatening when managed by frequent clinical observation and surgical removal, it is a 
concerning phenomenon pointing towards off-target side effects. Paradoxically, the use of 
BRAF inhibitors in non BRAF mutant tumours results in the activation of the MAPK 
pathway [36, 37], thus promoting cell proliferation and tumour progression. This finding 
highlights the critical importance of drug selection based on the presence of a BRAF 
V600E mutation within a patient‟s tumour, a concept that has now become known as 
personalised medicine. 
 
The BRAF inhibitor story demonstrates an excellent example of translational research in 
practice; moving from initial gene discovery to drug design, clinical trials and approval 
within a timeframe of 10 years. However, not all mutations discovered in tumours will 
require heavy investments in development. The availability of existing therapeutics, or „off 
the shelf‟ drugs, that have shown efficacy in malignancies with comparable mutation 
profiles, can be rapidly trialled for treatment of a new cancer type.   
 
An excellent example of this approach in metastatic melanoma is the use of Imatinib in 
KIT-mutated tumours. As mentioned previously, Imatinib is an inhibitor of tyrosine kinases, 
preventing substrate phosphorylation through competitive inhibition of the ATP-binding 
domain. In addition to activity in BCR-ABL mutant CML, Imatinib is also approved for 
gastro-intestinal stromal tumours (GIST), a cancer that exhibits oncogenic mutations of 
KIT in approximately 80% of patients [38, 39]. The positive response of Imatinib in GIST, 
combined with an early observation of KIT expression in melanoma, led to clinical trials of 
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Imatinib in metastatic melanoma. Although overall results of Imatinib lacked efficacy in the 
treatment of melanoma [40-42], closer analysis of a single patient who responded 
favorably identified them to harbour a mutation in KIT, suggesting putative efficacy of 
Imatinib in a subset of melanomas.   
 
Interestingly, sequencing analysis has revealed a distinct lack of KIT mutation in 
intermittently sun-exposed cutaneous melanomas but an increased representation of 
mutation in acral, mucosal and chronically sun-exposed melanomas [43].  As the latter 
subtypes of melanoma are rare, the poor efficacy in early Imatinib trials was most likely 
explained by the under-representation of KIT-mutated tumours within the studies. 
Subsequent case reports have since demonstrated major responses to Imatinib in patients 
with KIT-mutated acral and mucosal melanoma [44-47], and more recently, in a phase II 
clinical trial [48]. 
 
1.3. Understanding the genetics of cancer- the identification of driver 
mutations 
 
The successful development and recent approval of two drugs for metastatic melanoma, in 
particular the molecular based targeted approach of Vemurafenib, can be attributed to the 
extensive effort in understanding the genetic aetiology of melanoma. Characterisation of 
the multitude of genetic alterations promoting the development and progression of 
melanoma has led to the identification of frequently mutated genes, of which, a proportion 
are amenable to therapeutic intervention.  
 
The discovery of mutated genes driving the development of cancer has dramatically 
changed over time with advances in technology. More recently, the advent of next-
generation sequencing has allowed unparalleled, unbiased analysis of the cancer genome. 
This section provides a brief history of large-scale sequencing strategies with particular 
emphasis on the somatic genetics of metastatic melanoma. 
 
1.3.1. DNA sequencing by capillary electrophoresis  
 
Early investigations into the genetic aetiology of cancer relied strongly on candidate gene 
approaches for gene discovery. This included the analysis of cancer prone families via 
7
linkage analysis, positional cloning and subsequent in vitro transformation assays.  
Although these candidate gene approaches have the capability to reveal genes implicated 
in disease, these methods are primarily efficient for the identification of highly mutated 
genes and less so for those mutated at low frequency. The ability to screen large numbers 
of genes simultaneously in an unbiased manner was thus highly desirable [49]. It was the 
completion of the human genome project that provided a catalyst for improving existing 
sequencing techniques and led to significant increases in throughput capability, improved 
bioinformatics, and provided infrastructure to perform large scale sequencing efforts.  
 
Initial large scale sequencing efforts first focused on the sequencing of gene families; not 
surprisingly, members of the kinase family were first to be analysed due to their frequent 
involvement in cancer and potential to be targeted therapeutically [50].  One of the earliest 
studies sequenced the entire family of tyrosine kinases, representing 90 genes, in 35 
colorectal cancer cell lines [51]. The data suggested that approximately 30% of colorectal 
cancers have a mutation within the tyrosine kinome, and that potentially, other mutations 
may reside in alternative kinase families.  Another study extensively sequenced the 
tyrosine kinase family in 254 tumour cell lines of various tissue origins, including 53 
melanomas [52]. Interestingly, melanoma had the highest rate of mutation, with nearly all 
tumours having a mutation within a tyrosine kinase. 
 
Logically, the next progressive step forward involved sequencing of the entire complement 
of kinases in the human genome; this was completed in breast cancer [53], lung cancer 
[54] and testicular germ cell tumours [55]. The most comprehensive of these projects 
sequenced 210 tumours from a variety of cancers including 6 melanomas [56]. Again, 
melanoma had one of the highest rates of mutation, with approximately 24 somatic kinome 
mutations per sample tested; this either indicated the importance of kinases in 
melanomagenesis or that a high rate of mutation may be a feature inherent to melanoma. 
Regardless, these studies began to highlight the complexities of large scale sequencing 
efforts, including the difficulty in the identification of critical mutations contributing to the 
neoplastic process. 
 
Mutations are thought to stochastically accumulate within the genome, a large majority of 
which are not likely to confer a growth advantage to the cell.  This type of mutation, known 
as a „passenger‟ mutation event, will also be intrinsically present prior to and gained during 
clonal expansion of the tumour. In contrast, a small handful of mutations that are 
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deleterious or oncogenic in nature will be responsible for „driving‟ the process of 
tumorigenesis.  One of the main challenges faced in analyzing large amounts of data 
produced from genome-wide studies is determining „passenger‟ mutations from „driver‟ 
mutations [57]. 
 
„Driver‟ mutations in genes causally involved in tumorigenesis have been putatively 
labelled as cancer genes (CAN). A central aim in cancer research has been to identify 
CAN genes in order to understand the complex process of oncogenesis.  „A census of 
human cancer genes‟ using existing literature was the first step in cataloguing all CAN 
genes known to have a causal role in progression of a variety of cancer types [50, 58].  
Although originally 291 CAN genes were identified (approximately 1% of the genome), 
continuing research efforts have now identified a total of 474 CAN genes [58]. 
 
Cancer progression can be considered as a gradual accumulation of „driver‟ mutations in 
CAN genes. Original estimates based on theoretical models suggested as little as three 
mutations could be sufficient for tumorigenesis [59, 60]. However, early large scale 
sequencing efforts utilising traditional Sanger sequencing in colorectal and breast cancer 
revealed that individual tumours accumulated an average of 90 mutated genes, with a 
predicted average of 16 genes contributing to the neoplastic process [61].  Although 
revealing a higher complexity than previously predicted, this study was far from 
comprehensive as only half the coding region of the genome was sequenced in a low 
number of tumours (11 of each tumour type). 
 
Subsequent investigations sequenced even larger proportions of coding regions in 
cancers, further revealing the complexity of the cancer genome. Large scale Sanger 
sequencing projects assessing close to the entire coding region of the genome (from 
18000 to 20000 genes) was completed in breast and colorectal cancer [62], pancreatic 
cancer [63] and glioblastoma [64]. The extent of these studies revealed large differences in 
the genes mutated between individual tumours, with few genes frequently being mutated 
in a large proportion of samples. The majority of mutations in genes occurred in less than 
5% of all tumours tested. These 'mutation profiles' presented an interesting dilemma in 
interpreting the precise roles of mutations promoting tumour progression. Is cancer 
progression largely driven by a small number of genes frequently mutated in a large 
proportion of tumours (termed 'mountains' – possibly equivalent to „drivers‟), or is it the 
9
accumulation of large numbers of infrequent mutations responsible for driving tumour 
growth (termed 'hills' - possibly equivalent to „passengers‟), or some combination of both?  
 
To further elucidate the relevance of 'hill' CAN genes in respect to specificity of these 
mutations occurring between tumour types, one investigation used 27 of these 'hill' CAN 
genes identified in breast and colorectal cancer [62] to screen for mutations in melanoma, 
glioblastoma and pancreatic cancer [65]. Only 4 of these CAN genes were shown to be 
reciprocally mutated in melanoma and pancreatic carcinoma while no similar mutations 
were identified in glioblastoma. From these results, it was suggested that 'hill' CAN genes 
are not shared between tumours derived from different tissues and that each cancer type 
has a distinct mutation profile and genomic landscape.  
 
Although large scale efforts using traditional sequencing technology answered some early 
yet critical questions in cancer genetics, the associated costs and throughput capabilities 
of the technology was limiting comprehensive investigations into the cancer genome. The 
advent of next-generation sequencing platforms provided a viable, unbiased, cost effective 
solution for high-throughput genetic analysis. 
 
1.3.3. The application of next-generation sequencing technology 
 
Following the completion of the first draft of the human genome in 2001 [66, 67], a number 
of sequencing platforms were developed using novel chemistries allowing unparalleled 
data generation compared to DNA sequencing by capillary electrophoresis.  These next-
generation sequencing technologies, or massively parallel sequencing, allowed the whole 
genome of an individual to be sequenced for one hundredth the cost of Sanger dideoxy 
chemistry and in a timeframe of months [68-70].  These sequencing efforts were critical for 
the establishment of the methodology, alignment programs and bioinformatics required for 
the data generated from next-generation sequencing platforms.  
 
A seminal paper for cancer genomics was released in late 2008 when an entire acute 
myeloid leukaemia (AML) genome and its matched normal counterpart were characterised 
using next-generation sequencing [71]. This was the first glimpse into the genetic 
architecture of a tumour and provided a methodological template for somatic mutation 
analysis of cancer genomes. In particular, this project highlighted the necessity for 
sequencing not only the tumour at high depth, but also a matched normal sample in order 
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to differentiate between inherited germline variants and mutations acquired during 
tumorigenesis, albeit at an increased expense.   
 
A total of 10 non-synonymous mutations were identified in the cytogenetically normal AML 
genome, indicating that somatic mutations in this genome are extremely rare [71]. Of these 
mutations, two were well known AML-associated mutations while the remaining eight had 
not been previously documented. Although half of the eight mutations had been linked to 
genes involved in cancer pathogenesis; none of these genes would have been selected for 
hypothesis-driven candidate gene studies, thus highlighting the benefits of unbiased 
cancer genome sequencing analysis.  
 
In 2009, the second AML genome was sequenced, revealing a number of new mutations 
in genes not previously associated with AML [72]. A total of 64 somatic mutations were 
identified including 12 non-synonymous mutations. Surprisingly, none of the non-
synonymous mutations identified overlapped with the first AML genome; this was an initial 
indication of the heterogeneity of tumours and suggested that uncovering the complexity of 
cancer will require the sequencing of numerous cancer genomes. However, genotyping of 
the 12 non-synonymous mutations in an additional cohort of AML tumours revealed 15 of 
187 samples with mutations in IDH1, demonstrating the ability of cancer genomics to 
identify causal drivers of tumorigenesis. 
 
The first catalogue of somatic mutation of a melanoma genome involved the sequencing of 
a commercially available metastatic melanoma cell line, COLO-829, and its matched 
lymphoblastoid cell line, COLO-829BL [73]. As this melanoma cell line had been 
extensively studied, this analysis provided an opportunity to accurately assess the 
sensitivity of the sequencing method employed. A total of 42 of 48 known mutations within 
this cell line were detected, indicating a sensitivity of 88%. In all, 292 somatic mutations 
were found, of which, 187 were non-synonymous; a mutation rate considerably higher than 
that of AML or the first solid cancer that was sequenced prior (breast cancer) [74].  
 
Interestingly, analysis of the somatic base substitutions in COLO-829 revealed a mutation 
profile consistent with a UV radiation based carcinogenic signature [75].  The majority of 
mutations detected were C>T (G>A) transitions with ~70% being CC>TT/GG>AA, this is 
expected to be caused by DNA damage by UV radiation resulting in the formation of 
covalent links between two adjacent pyrimidines [76]. A carcinogenic signature of 
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G>T/C>A transversions has since been identified in small-cell lung cancer through 
excessive tobacco exposure [77].  
 
To assess the significance of mutations identified in COLO-829 in regards to driver versus 
passenger events, one approach is to use the non-synonymous to synonymous (N:S) 
mutation ratio [56, 78]. This statistic implies the assumption that non-synonymous 
mutations are biologically selected for as these mutations can affect the structure of 
proteins. As such, higher N:S ratios indicate positive selection overall compared to what is 
expected by chance. The N:S ratio of the COLO-829 genome was 1.78, not higher than 
the N:S ratio of 2.5:1 predicted for non-selected passenger mutations; this indicated that 
the majority of mutations were likely to be passenger mutations not relevant for 
pathogenesis of melanoma. This observation, in conjunction with high mutation rates in 
melanoma compared to other malignancies, highlights a potential difficulty in identifying 
causal genes involved in this disease. One approach to overcome this problem is by 
analyzing large numbers of tumours to identify frequently mutated genes.  
 
Integrative analysis of RNA-seq and high-resolution chromosomal copy number data was 
an early approach to comprehensively assess the mutation rate in a large subset of 
melanomas [79]. Although a number of interesting mutations were identified, this study 
was limited by the detection of mutations in the most abundant transcripts expressed in 
melanoma and the lack thereof of a matched normal sample for comparison. An 
improvement of this method involved the application of whole-exome sequencing (WES) 
strategies to cancer genomics. This led to the first exome report of 12 metastatic 
melanomas and their matched normal samples in mid 2011 [80]. Although the N:S ratio 
was 2.0:1, suggesting the majority of mutations were passenger mutations, a number of 
interesting genes were identified when the list of mutations was compared between 
samples. This led to the identification of a recurrent mutation of TRRAP in 4% of 
melanomas, as well as the identification of 25% of melanomas exhibiting mutations in 
GRIN2A (discussed in more detail later). Despite the high burden of mutation in 
melanoma, this study provided a proof of principle that genes relevant to the pathogenesis 
of the disease could be detected with small sample sets. 
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1.4. Genetics of cutaneous metastatic melanoma  
 
Since the identification of BRAF mutations in melanoma, studies have identified a number 
of oncogenes and tumour suppressor genes involved in a variety of pathways, including 
cell signalling, division and apoptosis. As the introduction of new technologies is making 
powerful genome-wide scale studies achievable, it is becoming apparent that determining 
affected pathways, rather than single genes in isolation, will be important in understanding 
tumorigenesis [81]. This section reviews the well-characterised classical pathways of 
cutaneous melanoma development in addition to novel emerging pathways revealed by 
recent sequencing efforts (Figure 1.2).  
 
1.4.1.   Classical pathways to melanoma development 
 
1.4.1.1. The mitogen-activated protein kinase (MAPK) pathway 
The MAPK pathway regulates cell growth regulation and survival through a series of 
signalling cascades in response to external stimuli (reviewed extensively in [82]). Under 
normal physiological conditions, extracellular signals initiate the binding of receptor 
tyrosine kinases (RTK) to RAS, a membrane-bound GTPase at the cell surface 
membrane. This process leads to a series of downstream phosphorylation cascades 
causing stepwise activation of BRAF, MEK1/2 and ERK1/2, and ultimately leads to cell 
regulation of proliferation, angiogenesis, invasiveness and metastasis. Although ERK 
activity is tightly regulated in melanocytes, high constitutive activity of the MAPK pathway 
is frequently observed in melanoma, largely due to the acquisition of oncogenic mutations 
in members of this pathway [83, 84].   
 
Activation of the MAPK pathway in melanoma is predominantly driven by mutation of 
BRAF (approximately 50% of melanomas), however, some tumours exhibit mutations in 
RAS. RAS mutations have been observed in 10-20% of melanomas [85], the most 
frequently mutated member of this family being NRAS. Notably, mutations of BRAF and 
NRAS tend to be mutually exclusive (except for a few rare cases) indicating redundancy in 
their biological function.  
 
Mutations in MAP2K1 (MEK1) and MAP2K2 (MEK2) have also been recently identified in 
8% of metastatic melanomas through use of WES [86]. Interestingly, MAP2K1/2 mutations 
not only cause constitutive activation of the MAPK pathway, but can also be acquired in 
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drug resistant tumours following the use of BRAF inhibitors [30, 31].  Alternatively, 
mutations in an upstream RTK, such as KIT or ERBB4, can result in MAPK activation 
(these are described in other sections of this review).  
 
1.4.1.2. The phosphatidylinisitol-3-kinase (PI3K) pathway 
Apart from the MAPK pathway, NRAS also signals through phosphatidylinisitol-3-kinase 
(PI3K) to activate AKT [87, 88].  AKT interacts with a number of other signalling networks 
that control a variety of cellular functions including cell survival, proliferation, apoptosis and 
tumour cell chemo-resistance. A gene known as PTEN (phosphatase and tensin homolog, 
deleted from chromosome 10) negatively regulates this pathway by preventing 
downstream AKT signalling and controls cell cycle progression. 
 
Activation of the PI3K pathway in melanoma occurs primarily through NRAS mutation 
(~20%); however, mutations can also occur in PIK3CA and AKT, albeit at low frequencies 
[89, 90].  In contrast, PTEN mutation results in deregulation of the PI3K pathway through 
the loss of negative regulation of AKT. PTEN mutation has been observed at high 
frequency in melanoma and was originally identified by its frequent deletion in a number of 
cancers. A variety of mutations including missense and splice site mutations, deletions and 
insertions in PTEN have since been observed in up to 30-50% of melanomas [91, 92]. As 
mutation of NRAS results in the deregulation of both the MAPK and PI3K pathways, 
mutation of PTEN is generally associated with BRAF mutant tumours.   
 
1.4.1.3. The Rb pathway  
The Rb pathway, responsible for controlling cell cycle division and progression, is another 
frequently deregulated pathway in melanoma [93]. A key regulator of this pathway is 
CDKN2A (cyclin-dependent kinase inhibitor 2A), a tumour suppressor gene identified in a 
range of tumours including melanoma [94].  CDKN2A encodes two different proteins, 
p16INK4A and p14ARF through alternative transcription start sites and use of different 
reading frames. Similar to PTEN, deletion of a region of chromosome 9 (where CDKN2A is 
located) was observed in a number of melanomas, indicating the presence of a putative 
tumour suppressor gene [95]. Deletions of CDKN2A have since been observed in up to 
50% of melanomas [96]. 
 
The CDKN2A product p16INK4A negatively regulates cell division by inhibiting kinases 
CDK4 and CDK6 bound to CCND1. The CCND1-CDK4/6 complex, when not inhibited, 
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phosphorylates pRb (RB1), an active repressor of E2F-mediated gene transcription, 
allowing transcription of a variety of genes that promote cell cycle division. Besides 
inactivation of p16INK4A, isolated reports have also identified mutations within CDK4, 
CDK6, CCND1 and RB1 that can cause deregulation of this pathway [97-99].      
 
1.4.1.4. The TP53 pathway  
CDKN2A, through an alternative reading frame, encodes another tumour suppressor 
called p14ARF.  p14ARF is responsible for the inhibition of MDM2 which in turn regulates 
the activity of p53 (TP53), a well known tumour suppressor gene involved in DNA repair, 
apoptosis and cell cycle division [100].  One role of p53 is to activate p21 (CDKN1A) 
which, like p16INK4A, prevents the phosphorylation of pRb by binding to CDK2/CCNE1 
complexes. Besides inactivation of p14ARF, deregulation of the p53 pathway occurs 
through mutation or deletion of TP53 in approximately 20% of melanomas [101, 102].  
 
1.4.2.    Emerging pathways of melanoma development 
 
1.4.2.1. Receptor tyrosine kinases and protein phosphatases 
RTKs are cell surface receptors that respond to external stimuli and are responsible for the 
control of a variety of cellular processes. This class of kinase has been extensively studied 
due to their frequent involvement in tumorigenesis and ability to be targeted for 
pharmacologic inhibition [50, 103]. Early studies identifying frequent RTK mutation in 
cancer [53, 104], including KIT mutations in melanoma [105], suggested the possibility of 
other deregulated RTKs in the development of melanoma.  
 
To investigate this premise, Prickett et al. performed a comprehensive analysis of the 
tyrosine kinase family in melanoma [106]. A total of 99 non-synonymous mutations were 
found in 19 protein tyrosine kinases, with the highest frequency occurring in ERBB4 (19%), 
FLT1 (10%) and PTK2B (10%). Focusing on ERBB4, in vitro functional analysis revealed 
that mutation led to an increase in cell growth and receptor auto-phosphorylation activation 
but more importantly, cells transfected with ERBB4 mutation had increased sensitivity to 
the drug Lapatinib, a FDA approved ERBB pharmacological inhibitor [106]. These results, 
if confirmed through additional in vivo experiments, suggests that ERBB4 could be a bona 
fide target for existing ERBB inhibitors in this subset of patients.  
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Analysis of another group of RTKs identified the fibroblast growth factor family as having a 
putative functional role in melanoma progression. Sequence analysis of FGFR1-4 in an 
initial cohort of 47 melanoma cell lines, followed by additional sequencing of FGFR2 in 66 
samples revealed a total of 15 different mutations in FGFR2 (mutated in ~10% of all 
samples tested). Additional analysis revealed mutations in 3 of 28 metastatic samples and 
5 of 72 primary tumours. However unlike ERBB4, bioinformatic analysis and in vitro 
functional assays indicated that the majority of mutations in FGFR2 result in a loss of 
receptor activity [107]. Inactivation of protein function presents difficulties in regards to 
drug development; however, further investigation into the role of FGFR mutations in 
melanoma is warranted.  
 
Deregulation of protein tyrosine phosphatases (PTP), proteins that co-regulate the activity 
of tyrosine kinases, have also been identified in melanoma. PTPRD was first shown to be 
lost through homozygous deletion in melanoma [108]. Building on this finding, sequencing 
of this gene in melanoma revealed 10 mutations in PTPRD in 7 of 57 tumours (12%) [109].  
Lentiviral transfection assays of mutated forms of PTPRD led to a decrease in cell death 
compared to transfected wild type PTPRD, contributing further evidence of a tumour 
suppressing role for PTPRD in melanoma. The entire extent of the role that deregulated 
PTP plays in melanoma has yet to be determined; it remains to be seen whether these 
proteins are viable therapeutic targets.  
 
1.4.2.2. G protein coupled receptors and glutamate signalling 
The first study using WES analysis in metastatic melanoma provided a glimpse into the 
melanoma genome and identified a number of novel recurrently mutated genes [80]. Aside 
from BRAF, the most frequently mutated gene found in this discovery screen was 
GRIN2A, which was mutated in ~25% of melanomas. Mutations occurred throughout the 
entire length of the gene and were most likely inactivating, suggesting that GRIN2A acts 
as a tumour suppressor.   
 
GRIN2A, an N-methyl-D-aspartate (NMDA) receptor, belongs to a class of ionotropic 
glutamate-gated ion channels. Binding of glutamate to GRIN2A allows calcium and 
potassium to traverse the cell membrane, however, the biological effect of GRIN2A 
mutation and its role in melanoma has yet to be determined. Targeted exon capture paired 
with next-generation sequencing of the G protein coupled receptor (GPCR) family in 
melanoma identified mutations in members of a second class of glutamate receptors, the 
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metabotropic glutamate receptors [110]. This included mutation of GRM3 and GRM8 in 
~16% and ~9% of melanomas respectively. Biochemical analysis of mutant GRM3 showed 
that it caused an increase in anchorage-independent growth and migration in vitro and in 
vivo.  
 
Additional evidence for the role of this emerging pathway in melanoma is demonstrated by 
mutation of PLCB4, a downstream effector of GRM signalling [80].  Other members of the 
GRM family have also been implicated in melanomagenesis; this includes the correlation 
of GRM1 expression to hyper-proliferation of mouse melanocytes and increased 
expression of GRM1 in human melanoma biopsies compared to melanocytes [111]. Lastly, 
mutant GRM3 was shown to increase the activation of MEK, possibly suggesting crosstalk 
between the MAPK and glutamate pathways.  Mutant GRM3 exposed to AZD6244, a small 
selective molecular inhibitor of MEK, resulted in greater inhibition and drug sensitivity 
compared to wild-type GRM3, suggesting this may be a viable drug strategy in patients 
with mutations of the glutamate pathway [111].  
 
1.4.2.3. Extracellular matrix regulation 
A number of recent studies have identified frequent mutations in gene families involved in 
the regulation of the extracellular matrix and may have a role in cell motility, invasion or 
metastasis. These studies combined have resulted in the emergence of a novel pathway 
to melanoma development. 
 
Matrix metalloproteinases (MMP) belong to a family of 23 proteolytic enzymes that 
degrade the extracellular matrix and basement membranes surrounding cells. The role of 
MMPs in cell invasion, including that of melanoma, has long been identified [112], 
however, investigations into somatic mutations within this family of proteins has only 
recently been performed [113]. Mutations were found in 8 MMP genes in 23% of 
melanomas, of these, MMP8 and MMP27 were most frequently mutated.  Interestingly, 
mutant MMP showed a decrease in proteolytic activity but an increase in tumour growth 
both in vitro and in vivo [113]. These results suggested that wild type MMP8 has the ability 
to inhibit melanoma progression and subsequently has a putative tumour suppressing role. 
 
Another related family, disintegrin-metalloproteinases with thrombospondin domains 
(ADAMTS), is part of a larger superfamily of zinc-based proteinases called metzincins, to 
which the MMPs belong. The role of ADAMTS proteins in cancer has not been well 
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established, however, ADAMTS15 was shown to be genetically inactivated in colorectal 
cancer [114]. This prompted mutational analysis of the ADAMTS family in melanoma [115], 
a study which identified a large fraction of tumours (~37%) harbouring mutations in 11 of 
the 19 genes comprising the family.  Mutant ADAMTS18, the most frequently mutated 
member at ~18%, was shown to be critical for cell migration in vitro and caused increased 
metastases in vivo, suggesting an oncogenic role in the proliferative, migratory ability of 
metastatic melanomas [115].   
 
Mutational analysis of a third family of the metzincins, the disintegrin-and 
metalloproteinases (ADAM) family, also revealed high rates of mutation in melanoma 
[116].  The ADAM family is a group of membrane-bound glycoproteins that have a variety 
of biological roles including cell adhesion, migration and proteolysis. Sequencing of the 19 
ADAM family genes revealed 8 genes collectively being mutated in 34% of melanomas, 
the most frequently occurring in ADAM7 (~12%) and ADAM29 (~15%). Functional analysis 
demonstrated that mutant ADAM7/29 affected the adhesion capacity to a variety of 
extracellular matrix proteins and increased migratory abilities.  
 
Although early clinical trials investigating first generation pan-inhibitors of proteolytic 
activity of MMP yielded disappointing results [117], numerous investigations using novel 
approaches targeting secretase activity are currently underway [118].  
 
1.4.2.4. Transcriptional and chromatin modification 
Micropthalmia-associated transcription factor (MITF) is a key regulator of melanocyte 
development controlling a variety of processes such as pigmentation, apoptosis and cell 
cycle progression. In an early study using high density SNP arrays to investigate 
chromosomal copy number change in the NCI60 panel of cell lines, amplifications at a 
locus on chromosome 3p were identified that defined the melanoma subcluster [119]. 
Within this region, MITF was the only gene that correlated highly between amplification 
and high transcript expression. Subsequent analysis revealed that 10-20% of melanomas 
exhibited amplification of MITF and that deregulation, in combination with BRAF V600E 
mutation, was capable of melanocyte transformation [119]. As such, somatic alteration of 
MITF by amplification was suggested to define a specific oncogenic subclass based on 
„lineage survival‟ or „lineage addiction‟.   
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Further analysis of MITF revealed that in addition to amplification, somatic mutation also 
occurs in ~8% of cutaneous melanomas [120].  Additionally, a gene upstream of MITF, 
SOX10, was found to have putative inactivating mutations in a small proportion of 
melanomas; these mutations occurred in a mutually exclusive pattern, possibly indicating 
functional redundancy between both events. Both of the aforementioned studies 
documented a distinct association between MITF and BRAF mutation and mutual 
exclusivity to NRAS mutation. MITF has been shown to act through the TP53 and RB1 
pathways [121] and recently was characterised for direct interactions of genes involved in 
DNA replication, repair, and mitosis [122]. Due to the complexity of MITF interactions, 
additional studies will be required to determine if this critical gene in melanocyte biology 
can be targeted therapeutically. 
 
Studies have also revealed a number of other genes implicated in melanoma development 
that are involved in transcriptional control and chromatin modification. WES analysis 
performed by Wei et al. revealed a recurrent mutation in a novel gene, TRRAP, with a role 
in transcription and DNA repair and complexes with histone acetyltransferases [80]. 
Mutations in TRRAP clustered locally, similar to BRAF, PIK3CA and RAS, suggesting that 
TRRAP may be a new oncogene involved in metastatic melanoma.  TRRAP mutation 
occurred in ~4% of melanomas and mutant TRRAP was shown to be essential for cell 
survival and transformation [80].  
 
In further regard to chromosomal copy number alterations, functional screening using a 
zebrafish melanoma model revealed SETDB1 in a region of recurrent amplification of 
human chromosome 1 that can cooperate with BRAF (V600E)  [123]. SETDB1 is a histone 
methyltransferase and contributes to cellular functions involving histone methylation, gene 
silencing and transcriptional repression. Alternatively, homozygous deletions in a histone 
deacetylase, HDAC4, have also been documented in metastatic melanoma, although the 
consequences of deletion have not been determined [108].  With increasing WES reports 
identifying mutations in histone and chromatin modification genes in cancer [124, 125]; it 
will be interesting to see how this class of mutations contributes to the development of 
melanoma and whether they are amenable to histone deacetylase inhibition. 
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1.5. Genetics of non-cutaneous metastatic melanoma 
 
Melanomas of the skin (cutaneous melanoma) account for approximately 90% of all 
diagnosed melanomas; the remaining melanomas arise within the eye (uveal ~5%), or 
from mucosal membranes of the body (mucosal ~2%) [126]. A small proportion, although 
of cutaneous origin, occur in typically non-UV-exposed regions of the body such as the 
palms or sole of the feet (acral ~5%), and are classified as a distinct subtype of melanoma 
(Figure 1.3). The common feature between these rare forms of melanoma is that they 
have distinct genetic alterations or profiles compared to melanomas of cutaneous origin.  
 
In a seminal study in 2005, Curtin et al. assessed chromosomal copy number changes in 
126 melanomas from a variety of subtypes, including acral, mucosal, and cutaneous 
melanoma with or without chronic sun exposure [127]. Interestingly, each of these groups 
had significantly different sets of chromosomal aberrations and could accurately be 
categorised based on these profiles.  In addition, this study revealed a lack of BRAF/NRAS 
mutation in non cutaneous melanomas and was associated with increased copy gains of 
CDK4 and CCND1. This indicated that the underlying mechanisms behind the 
development of these tumours are fundamentally different to cutaneous melanoma. This 
section provides a brief summary of the genetics of non-cutaneous melanoma (Figure 1.4) 
and the associated approaches to therapy.  
 
1.5.1.  Uveal melanoma 
 
Uveal melanoma arise anywhere within the uveal tract, including the choroid plexus, ciliary 
body or iris, and account for approximately 5% of all melanomas [126]. Melanomas of the 
choroid or ciliary body, classed as „posterior uveal melanomas‟, represent approximately 
90% of all uveal melanomas and are clinically distinct from iris melanomas. Notably, uveal 
tumours lack mutations in BRAF or NRAS, this is despite the presence of constitutive 
activity of the MAPK pathway [128].  The discovery of hypermorphic mutations in GNAQ 
and GNA11 in dermal hyper-pigmented mice from mutagenesis screens led to sequencing 
of these genes in melanoma [129]. This study found somatic mutations of GNAQ in 83% of 
blue naevi and 46% of ocular melanoma of the uvea [130]. With remarkable similarity to 
BRAF, mutation of GNAQ nearly exclusively occurs in a single coding position (Q209) 
locking the GTPase in a manner that leads to constitutive activity and downstream 
signalling of the MAPK pathway. 
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Cutaneous melanoma 
` 
Acral lentigenous melanoma (ALM) occurring on the sole of the feet  (left) and on the thumb (right) 
Non-cutaneous melanoma 
Superficial spreading 
melanoma (SSM) 
Nodular melanoma 
(NM) 
Lentigo maligna 
melanoma (LMM) 
Mucosal melanoma of the lower lip (left) and inner cheek (right)  
Fundus photography (left) and ultrasonography  (centre) of a choroid uveal melanoma. 
The picture on the right depicts an iris uveal melanoma.  
Figure 1.3: The different subtypes of melanoma (primary sites shown). Approximately 
90% of melanomas are of cutaneous origin; the most frequently diagnosed form being 
superficial spreading melanoma (SSM). Uveal melanomas (~5%) and mucosal 
melanomas (~2%) are less frequently diagnosed. Percentages of incidence are indicative 
of a Caucasian population. Figures adapted from [14, 148-150]. 
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Figure 1.4: Genetics of non-cutaneous melanoma. 
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 A subsequent study that sequenced the highly homologous gene family member GNA11, 
led to the identification of reciprocal mutations in 7% of blue naevi, 32% of primary uveal 
melanoma and 57% of uveal melanoma metastases [131].  Interestingly, mutation of 
GNA11 occurs mutually exclusively to GNAQ mutations; together these mutations account 
for ~85% of uveal melanomas and are unique to this tumour type. As both genes lead to 
activation of the MAPK pathway, it was proposed that drugs targeting this pathway, such 
as MEK inhibitors (AZD6244), may represent an effective therapeutic avenue. Currently, 
clinical trials using this approach in uveal melanomas are underway, however, a recent 
study revealed only mild sensitivity to AZD6244 of GNAQ mutant uveal cell lines in vitro 
[132].  
 
Uveal melanomas can be classed based on their metastatic capability, class 1 (low risk) 
and class 2 (high risk); and until recently, not much was known about the genetic basis of 
either class. Although mutations can occur in GNAQ and GNA11, these appear to be an 
early event during tumorigenesis (as demonstrated by their presence in benign lesions or 
blue naevi) and are not correlated with a particular class [131]. Furthermore, transcriptomic 
and genomic profiling of class 1 and 2 uveal melanomas revealed a striking propensity for 
chromosome 3 monosomy in class 2 high risk metastases [133]; this suggested that loss 
of an allele on this chromosome could expose an inactivating mutation on the remaining 
allele that promotes metastasis.  
 
Exome sequencing of two class 2 tumours and their matched normal counterparts 
revealed inactivating mutations in BAP1 (encoding BRCA1 associated protein 1) on 
chromosome 3p21.1 [134]. Mutation screening of BAP1 in a larger cohort of tumours 
revealed mutations in 26 of 31 class 2 (84%) and only 1 of 26 (4%) class 1 uveal 
melanomas, revealing a strong selection for metastatic tumours [134].  BAP1, a nuclear 
ubiquitin carboxyterminal hydrolase, appears to have a complex role, with binding domains 
for the tumour suppressors BRCA1 and BARD1, and can complex with the histone-
modifier HCFC1. Although targeting of this gene in a therapeutic sense is challenging, 
inhibition of RING1 deubiquitinating activity may be a viable approach [134]. 
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1.5.2. Acral and mucosal melanoma 
 
Acral melanomas are rare cutaneous melanomas that occur in non-hairy regions of the 
skin including the soles of the feet, palms or nail-bed.  This form of melanoma is the 
predominant subtype in non-Caucasians and is associated with a worse prognosis than 
cutaneous malignant melanoma overall [135].  Due to its location on the body, acral 
melanoma is typically associated with a non UV exposure profile.  
 
The first glimpse into the genetic architecture of acral melanoma was recently reported 
through the whole genome sequencing of a chemo-naïve primary acral melanoma and its 
matched lymph node metastasis [136]. Not surprisingly, the total number of 
nonsynonymous mutations detected in these tumours was 40, about 10 fold less than that 
of observed rates of sun exposed cutaneous melanomas (typical range of 200-600). This 
rate of mutation is also consistent with the observed rates in non-carcinogen exposed 
cancers such as breast [74] and prostate [79]. Interestingly, the type of mutation was 
largely typical of a UV based signature with 60% exhibiting C>T (G>A) transitions; 
however, it was suggested that this might be due to a nonsense mutation in ERCC5, a 
gene responsible for the repair of dipyrimidine lesions.  Although this tumour did not have 
a point mutation in KIT, it did exhibit strong amplification of the gene.    
 
Mucosal melanomas are even rarer (~2% of all melanomas) and occur in mucosal 
membranes of the body including the oral/nasal cavity, anorectal region, urinary tract or 
genitalia. This subtype is even less characterised than acral melanoma, however, both 
subtypes share a high propensity for KIT mutation; it was shown that 39% of mucosal and 
36% of acral melanomas had a mutation in KIT, while none were detected in non chronic 
sun damaged cutaneous melanomas [43]. This is of clinical relevance due to the positive 
response of Imatinib in KIT-mutated GIST [39]. Subsequently, this has prompted similar 
investigations of Imatinib in KIT mutated melanomas including recent phase II trials 
demonstrating significant activity [48, 137]. Unlike BRAF, mutation of KIT can occur 
throughout the entire gene; interestingly, the majority of responders had mutations in 
exons 11 or 13, suggesting that further selection criteria for drug eligibility may be 
beneficial.   
 
Trials into other KIT inhibitors are also currently in progress, including the recent 
completion of a Sunitinib trial of KIT-mutated melanoma [138]. It will be interesting to 
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compare the activity of these drugs, particularly in regard to their efficacy in targeting the 
variety of mutation events observed in KIT. In summary, although these tumours are rare, 
further genomic characterisation is warranted. This will lead to a deeper understanding of 
the genetic mechanisms in effect, potentially leading to new therapeutic avenues that may 
be relevant to other subtypes of melanoma. Access to tumour material and subsequent 
enrolment in clinical trials will remain a challenge for these rare subtypes of melanoma.  
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1.6.  Rationale of this study  
 
Metastatic melanoma has historically been difficult to treat and is refractive to traditional 
chemotherapeutic strategies. The approval of two new drugs in 2011, Ipilimumab and 
Vemurafenib, are the first drugs in 20 years that have improved rates of overall survival in 
patients. The success of these drugs, particularly the latter, have stemmed from earlier 
efforts in understanding the complex mechanisms behind the development and 
progression of metastatic melanoma. Thus, cataloguing the diverse range of mutations in 
melanoma will ultimately reveal undiscovered targets for which effective therapeutics may 
be designed, or alternatively, identify mutations that can dictate the efficacy of current drug 
strategies. 
 
This study aims to extensively characterize a panel of stage III local lymph node metastatic 
melanoma cell lines using a range of high-throughput technologies, including next 
generation sequencing, to identify novel genes and therapeutic targets in metastatic 
melanoma. At the beginning of this thesis, next-generation technology had not been used 
to assess the melanoma genome and hence, provided the opportunity to thoroughly 
investigate this cancer at unprecedented depth. By layering data from multiple high-
throughput technologies in a complementary manner, the limitations of each technology 
individually can be overcome. Using this approach, this study will identify numerous 
mutations that will hopefully be translated into effective therapeutic treatments for patients 
with metastatic melanoma (Figure 1.5). 
 
The panel of stage III melanoma cell lines was established by the Cancer Immunotherapy 
Laboratory at the Queensland Institute of Medical Research from treatment naïve tumours 
collected prior to a clinical trial (see appendix for selection criteria). This panel is a 
valuable source from a research perspective as the use of cell lines allows the extensive 
generation of materials required for experimental work, and can also be used for 
downstream functional analysis.  
 
Although cell lines can acquire genetic mutations as a result of the culturing process, the 
impacts of this effect have been minimized in this project. Firstly, these cell lines have 
been established at the earliest passage to reduce the possibility of cell culture acquired 
mutations. As such, stocks of DNA and RNA, on average, were collected at passage nine. 
Where available, remaining portions of tumours were retained, stored, and extracted for 
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DNA.  Thus, for any mutations identified in the melanoma cell lines, matching tumour DNA 
can be used to ascertain the presence of the aforementioned mutations within the original 
tumour to determine the possibility of cell culture acquired artifacts. Early passage 
lymphoblastoid cell lines (LCL) have also been established for the majority of these 
melanoma cell lines and represent a matched normal genomic specimen. This enables 
germline variants to be distinguished from somatically acquired tumour mutations by 
subsequent screening of cell line mutations in matching LCL.  
 
Tumour specimens are heterogeneous in nature by the presence of contaminating stromal 
cells; this reduction in purity is important in the context of genetic analysis and can result in 
the false negative identification of mutations. In contrast, cell lines are typically more 
homogeneous and can overcome said contamination problems associated with tumour 
specimen analysis; however, in the same sense, the process of cell culturing can select for 
and allow outgrowth of specific subpopulations within the tumour and can lead to an 
under-representation of the true mutational complexity.  
 
In regards to chromosomal copy number analysis using high density SNP arrays, 
comparison of primary neuroblastoma tumours and matching early-passage cell lines (~7 
passages) identified a significant underestimation of LOH and copy loss events in tumours 
due to stromal contamination; this suggested that low passage cell lines may be superior 
specimens for genome-wide SNP array studies. [139]  The use of next-generation 
sequencing to identify the overall concordance of single nucleotide mutations in matched 
tumour versus cell lines has not yet been published. However, unpublished data from our 
laboratory using whole-exome sequencing in early passage cell lines indicate a high 
concordance to matched tumours; this suggests that the acquisition of cell culture acquired 
mutations, at least at low passages, is low.  
 
The melanoma cell lines were established from stage III local lymph node metastases prior 
to therapy, including chemotherapy. An increase in mutation load or genotoxicity through 
chemotherapeutic regimens have been observed both in normal somatic cells [140] and 
tumours [141]. As such, analysis of tumour specimens prior to any systemic treatment 
alleviates the need for discerning treatment acquired mutations to mutations acquired 
during tumorigenesis. Reducing the complexity of mutation analysis is particularly 
important for genetic research into melanoma as this cancer inherently has a high 
mutation rate due to UV exposure [73].  
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 The panel of stage III metastatic cell lines represents an average clinical distribution of 
melanoma subtypes (Table 1).  The majority of melanomas are of cutaneous origin that 
presented as superficial spreading or nodular subtypes. No acral, uveal or mucosal 
melanomas are included in this cohort. For some patients complete clinical information 
could not be obtained. Unlike systemic disseminated melanoma (stage IV), patients with 
stage III melanomas present with metastases in local lymph nodes and exhibit 5 year 
survival rates between 27-70%; this is primarily dependent on the number of metastatic 
deposits present within the lymph nodes [142]. After lymph node dissection, approximately 
30% of patients will be recurrence-free; for the majority of patients however, recurrence 
can either occur locally at the primary site (~10%), regionally to the sentinel lymph node 
(12%), or distantly to other parts of the body (44%) [143]. As the majority of melanoma 
related mortality is accounted through disseminated disease, genetic analysis of the stage 
III melanomas will identify relevant mutations for patients that can be therapeutically 
targeted upon clinical presentation. 
 
1.7.  Specific aims of this study 
 
Aim 1: To perform an extensive characterisation of a panel of stage III local lymph node  
 metastatic melanoma cell lines. 
1.1. To establish cell line banks and extract DNA, RNA, miRNA and protein. 
1.2. To carry out mutational analysis of approximately 230 known oncogenic  
        mutations. 
1.3. To sequence select tumour suppressor genes known to be involved in melanoma. 
 
Aim 2: Use comparative genomic hybridisation with single nucleotide polymorphism arrays 
 to identify novel genes involved in focal DNA copy number changes.  
 
Aim 3: Use whole exome sequencing on metastatic melanoma cell lines to identify novel  
frequently mutated genes. 
 
Aim 4: Investigate BRAF/NRAS WT melanomas using whole-exome sequencing. 
 
Aim 5: Develop a melanoma specific mutation panel to identify clinically relevant “mutation  
profiles” in metastatic melanoma.  
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1.8.  Account of research progress linking the research papers  
 
The results presented in this thesis highlight the progressive nature of sequencing 
technology and its application to cancer genomics and personalised medicine.  
 
Firstly, independent early passage cell line stocks were generated from a bank of cell lines 
previously established at the Cancer Immunotherapy Laboratory at the Queensland 
Institute of Medical Research. Sufficient quantities of cells were then harvested for 
extraction of DNA, RNA, miRNA and protein, which were used for comprehensive genetic 
analysis. The generation of these stocks relate to Aim 1.1 of the thesis; details of the 
methods used are found within the materials and methods sections of Chapters 2 to 5.  
Results of melanoma tumour suppressor gene sequencing (Aim 1.2) and oncogenic 
mutation profiling (Aim 1.3) are included in Chapters 4 and 5 respectively. The results of 
Aim 1 collectively contribute to the entire thesis and are hence, apart from here, are not 
discussed independently.  
 
Chapter 2 describes the use of high density SNP arrays to identify chromosomal copy 
number changes involving focal amplification and focal homozygous deletions to reveal 
putative oncogenes and tumour suppressor genes, respectively [144]. Candidate gene 
sequencing of 5 genes in a larger cohort of samples revealed a putative tumour 
suppressor gene, TFG (TRK Fused Gene), being mutated in approximately 5% of 
melanomas.  Although the function of TFG is not properly understood, it has been shown 
to activate the MAPK pathway, indicating that mutation of TFG may have clinical relevance 
for drug strategies targeting this pathway.  
 
Although SNP arrays are cost effective, have high-throughput capabilities, and have the 
ability to identify genes implicated in cancer (as evidenced by the results of Chapter 2), the 
rapidly decreasing costs and unbiased analysis provided by next-generation sequencing 
have placed this technology competitively at the forefront of modern cancer research. As 
such, Chapter 3 describes the use of whole-exome sequencing (WES) in metastatic 
melanoma cell lines to identify novel genes involved in the aetiology of this disease [145]. 
The results of this study revealed mutually exclusive mutations of MAP3K5 and MAP3K9 
in 25% of melanomas, some of which may contribute to chemo-resistance in patients.  
Furthermore, this finding identifies a new pathway involving apoptosis that may be critical 
to the development and progression of metastatic melanoma.  
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 Next-generation sequencing has allowed the rapid identification of novel genes involved in 
cancer; however, it is important to place these findings in context of the molecular 
pathways they control. One pathway frequently deregulated in melanomas is the MAPK 
pathway; a pathway activated by mutation of BRAF and NRAS in 50% and 20% of 
melanomas, respectively. However, not much is known about the remaining 30% of 
melanomas that are BRAF/NRAS wild type (WT). To address this issue, Chapter 4 
describes the use of multiple genomic datasets, including WES, to determine if 
BRAF/NRAS WT melanomas are distinct molecular entities that may be susceptible to 
novel drug strategies. In summary, three of the four cell lines screened with WES had 
nonsense mutations in NF1, a negative regulator of NRAS, and potentially contributes to 
the activation of MAPK pathway in these cell lines. In addition, there is evidence to 
suggest that BRAF/NRAS WT melanomas with NF1 mutation may be amenable to mTOR 
inhibition by rapamycin thus identifying a novel therapeutic strategy for this subset of 
melanomas.  
 
Lastly, the identification of mutations occurring in melanoma has led to the successful 
development of molecular based targeted drugs, including the BRAF inhibitor 
Vemurafenib. However, positive clinical activity of these drugs relies strongly on the 
presence of mutations or „mutation profile‟ of the patient‟s tumour. In Chapter 5, the 
development of a high-throughput mutation screening panel for the identification of 
clinically relevant mutation profiles in melanoma is described [146]. The final panel, 
consisting of 39 mutations in 20 genes, identified a total of 252 mutations in 271 
melanomas including mutations in BRAF (n=154, 57%), NRAS (n=55, 20%), CDK4 (n=8, 
3%), PTK2B (n=7, 2.5%) and ERBB4 (n=5, 2%). This panel, when used in a clinical 
research setting, has the potential to rapidly and identify effective treatment strategies 
using novel or existing molecularly targeted drugs.  
 
The final chapters of this thesis discuss the abovementioned findings in regards to their 
application and relevance to current therapeutic approaches. Chapter 6 (Discussion) 
describes the limitations of next-generation sequencing technology in the detection of 
somatic mutations in melanoma through a perspectives article written for Pigment Cell and 
Melanoma Research [147].  Lastly, Chapter 7 (Conclusion) discusses the role of next-
generation sequencing in personalised medicine and how this technology is progressing 
into a clinical setting; this is explained in relation to the results presented in this thesis. 
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These results have led future investigations and experiments which are detailed in the last 
segment of the conclusion. 
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Chapter 2 
 
Identification of TFG (Trk-Fused Gene) as a putative metastatic 
melanoma tumour suppressor gene 
 
Ken Dutton-Regester, Lauren G. Aoude, Derek J. Nancarrow, Mitchell S. Stark, Linda 
O’Connor, Cathy Lanagan, Gulietta M. Pupo, Varsha Tembe, Candace C. Carter, Michael 
O’Rourke, Richard A. Scolyer, Graham J. Mann, Christopher W. Schmidt, Adrian 
Herington and Nicholas K. Hayward. Identification of TFG (TRK-Fused Gene) as a 
Putative Metastatic Melanoma Tumour Suppressor Gene. Genes, Chromosomes and 
Cancer. 2012. 51(5):452-61.   
 
 
2.1. Relevance to thesis aims 
 
This chapter addresses Aim 2 of the thesis by identifying novel genes involved in the 
development of metastatic melanoma using SNP arrays. SNP arrays have previously been 
utilised to identify changes in chromosome copy gain (amplifications) or loss (homozygous 
deletions) in metastatic melanoma and these events can be responsible for tumorigenesis.  
Identifying causal genes within large regions of copy number changes can be difficult to 
determine, however, regions of focal amplifications or homozygous deletions involving 
one, or a small number of genes, have the potential to identify putative oncogenes and 
tumour suppressor genes respectively.  
 
In this report, SNP arrays were used on a panel of 39 stage III metastatic melanoma cell 
lines to identify unbalanced chromosomal events. This revealed a number of genes 
previously implicated in the development of melanoma including CDKN2A, CDKN2B, 
PTEN, PTRPD and TP53 in regions of homozygous deletions and CCND1, MITF, MDM2 
and NRAS in regions of amplification. In order to identify novel genes that may contribute 
to the pathogenesis of melanoma, a filtering strategy was used to identify genes involved 
in focal amplification and homozygous deletions. A total of 5 genes within focal 
homozygous deletions were selected for further screening using traditional Sanger 
sequencing. One of these genes, TFG (Trk-Fused Gene), was shown to be mutated in 
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approximately 5% of samples and may have clinical relevance to current therapeutic 
strategies for treating metastatic melanoma.  
 
This study demonstrates the application of SNP arrays for identifying novel genes involved 
in melanoma tumorigenesis. Although significant decreases in costs associated with next 
generation sequencing will inevitably see this use of SNP arrays obsolete, the data 
produced from these arrays will remain valuable as companion data for next generation 
sequencing analysis. As such, the data produced from this study also contributes to 
Chapter 5; characterising the events involved in frequently mutated pathways in a panel of 
stage III metastatic melanomas.  
 
2.2. Contribution of candidate 
 
Initial project design and planning was conducted in association with supervisors. The 
harvesting of DNA from the C series of melanoma cell lines used in this study was 
performed with the help of Lauren Aoude. I generated and analysed the SNP array data, 
sequenced candidate genes and prepared the manuscript. 
 
2.3. Acknowledgment of the contribution of others 
 
The panel of C series stage III metastatic melanoma samples were collected by Michael 
O’Rourke and cell lines from these samples were established by Cathy Lanagan, Linda 
O’Connor and Christopher W. Schmidt.  Lauren Aoude contributed to the generation of cell 
line stocks and the subsequent extraction of DNA. SNP array data generation and analysis 
was compiled under the guidance of Mitchell S. Stark and Derek J. Nancarrow, 
respectively. An independent cohort of melanoma tumour and cell line DNA was prepared 
by members of the Melanoma Institute of Australia that included Gulietta M. Pupo, Varsha 
Tembe, Candace D. Carter, Richard A. Scolyer and Graham Mann. All authors reviewed 
and supplied comments on the final manuscript prior to publication.  
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Chapter 3 
 
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic 
melanoma identified by exome sequencing  
 
Mitchell S. Stark*, Susan L. Woods*, Michael G. Gartside*, Vanessa F. Bonazzi*, Ken 
Dutton-Regester*, Lauren G. Aoude, Donald Chow, Chris Sereduk, Natalie M. Niemi, 
Nanyun Tang, Jonathon J. Ellis, Jeffrey Reid, Victoria Zismann, Sonika Tyagi, Donna 
Muzny, Irene Newsham, YuanQing Wu, Jane M. Palmer, Thomas Pollak, David Youngkin, 
Bradford R. Brooks, Catherine Lanagan, Christopher W. Schmidt, Bostjan Kobe, Jeffrey P. 
MacKeigan, Hongwei Yin, Kevin M. Brown, Richard Gibbs, Jeffrey Trent and Nicholas K. 
Hayward. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma 
identified by exome sequencing. Nature Genetics, 2012. 44(2): p165-169.     
* These authors contributed equally to this work. 
 
3.1. Relevance to thesis aims 
 
The results of this manuscript contribute to Aim 3 of the thesis and describe the use of 
whole-exome sequencing (WES) in 8 metastatic melanoma cell lines.  Advances in next 
generation sequencing technology have recently enabled unbiased, cost effective and 
comprehensive mutation analysis. Use of WES in matched tumour and normal DNA has 
the potential to identify the entire catalogue of mutations occurring within the protein 
coding region of the human genome. This is of relevance to this thesis as nonsynonymous 
mutations, those mutations that result in a change to protein sequence, may have 
significance to, or may be amenable to therapeutic intervention. Furthermore, overlaying 
WES data from multiple melanomas has the ability to identify genes that are frequently 
mutated and are thus more likely to be ‘drivers’ of tumorigenesis.  
 
WES was used to sequence 8 matched metastatic melanoma cell lines and 
lymphoblastoid cell lines to identify somatically mutated genes. A large number of 
mutations were identified within each melanoma, highlighting the difficulty of identifying 
putative mutations driving tumour growth compared to benign passenger mutations. Two 
mutated genes, MAP3K5 and MAP3K9, were selected for further sequencing in a larger 
series of samples due to their putative significance to current therapeutics. This identified 
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mutually exclusive mutations in MAP3K5 and MAP3K9 in approximately 9% and 15% of 
samples respectively. Functional analysis of select mutations in MAP3K5 and MAP3K9 
suggested these mutations were inactivating, resulting in a reduction of kinase activity and 
downstream signalling of apoptotic pathways. Lastly, the use of siRNA to knockdown 
MAP3K9 activity led to an increase in cell viability after temozolomide treatment, 
suggesting that decreased MAP3K9 activity can lead to chemo-resistance in melanoma.  
 
Prior to this publication, there was a single report of whole-genome sequencing on a 
commercially available melanoma cell line and a single report of WES in 12 metastatic 
melanoma cell lines. The current report confirmed the high rate of mutation in melanoma 
as compared to other cancer types, a phenomenon most likely explained by high UV 
radiation exposure from the sun. This was the first report to identify frequent mutations in 
the MAP3K family and subsequent reduction of downstream signalling of apoptotic 
pathways in melanoma. In summary, this report highlights the power of next generation 
sequencing technology in identifying novel genes responsible for the development and 
progression of melanoma in a cost effective and high-throughput manner. 
 
3.2. Contribution of candidate 
 
During the second year of my PhD, I visited the Human Genome Sequencing Centre at 
Baylor College of Medicine in Houston, Texas to undertake next generation sequencing 
using the Applied Biosystems SOLiD 3 system. A total of 5 matched metastatic melanoma 
cell lines and lymphoblastoid cell lines were sequenced and analysed, 4 of which 
contributed to the 8 samples screened by WES in this publication. The other samples in 
this study were sequenced on the Illumina GA2 platform at the Queensland Institute of 
Medical Research by Mitchell S. Stark and Michael G. Gartside. I performed confirmation 
sequencing and follow-up genomic sequencing of MAP3K5 in a panel of 85 metastatic 
melanoma cell lines, contributed to the design of Figure 1, and helped devise the potential 
significance of MAP3K5 and MAP3K9 mutation in regards to melanoma development. This 
project was a large collaborative effort that contained functional analysis that was outside 
the scope of my thesis. This was performed by colleagues and collaborators described 
below.  
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Experimental study design was devised by Nicholas K. Hayward, Kevin M. Brown, Richard 
Gibbs, and Jeffrey Trent. Mitchell S. Stark and Michael G. Gartside performed WES using 
the Illumina GA2 platform. Sonika Tyagi established the bioinformatics pipeline for 
analysing the WES data obtained using the Illumina GA2 platform. Jeffrey Reid, Donna 
Muzny, Irene Newsham and YuanQing Wu contributed to the WES data generation and 
analysis of samples sequenced using the SOLiD 3 platform. Susan L. Woods, Michael G. 
Gartside, Vanessa F. Bonazzi, Bradford R. Brooks, Donald Chow, Natalie N. Niemi, 
Jeffrey P. MacKeigan, Thomas Pollak and Hongwei Yin produced and analysed the 
functional data.  Jonathon J. Ellis and Bostjan Kobe performed protein modelling. Donald 
Chow, Chris Sereduk, Nanyun Tang and Hongwei Yin performed the TMZ and siRNA 
sensitization studies and RT-PCR. Confirmation sequencing was performed with the help 
of Mitchell S. Stark, Michael G. Gartside, Lauren G. Aoude, Victoria Zismann and David 
Youngkin. Christopher W. Schmidt and Catherine Lanagan established the melanoma cell 
line panel and provided fresh melanoma tumours. Jane M. Palmer extracted and collated 
clinical records for the melanoma patients. Mitchell S. Stark, Susan L. Woods, Michael G. 
Gartside, Vanessa F. Bonazzi, Jeffrey P. MacKeigan, Hongwei Yin, Nicholas K. Hayward 
and I wrote the manuscript. All authors read and approved the final manuscript.  
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Chapter 4 
 
Exome sequencing of wild-type BRAF and NRAS metastatic melanomas 
reveals novel mutations in known pathways of melanoma development 
 
Ken Dutton-Regester, Lauren G. Aoude, Mitchell S. Stark, Derek J. Nancarrow, Glen M. 
Boyle, Michael G. Gartside, Vanessa F. Bonazzi, Susan L. Woods, Cathy Lanagan, Linda 
O’Connor, Michael O’Rourke, Christopher W. Schmidt and Nicholas K. Hayward. Exome 
sequencing of wild-type BRAF and NRAS metastatic melanomas reveals novel mutations 
in known pathways of melanoma development- manuscript in preparation.    
 
 
4.1. Relevance to thesis aims 
 
This manuscript relates to Aim 5 and combines data that has been generated from the 
entire thesis, including Aim 1. Cancer, including melanoma, can generally be considered a 
genetic disease; that is a disease caused by the accumulation of mutation events over 
time. It is frequently observed that these mutations occur in particular molecular pathways, 
some of which are more frequently mutated in certain cancer types compared to others. 
One pathway that is frequently mutated in melanoma is the MAPK pathway, which 
includes NRAS and BRAF, genes that are mutated in approximately 20% and 50% of 
melanomas respectively. The remaining 20-30% of melanomas that are BRAF/NRAS wild 
type (WT) has not been extensively characterised. As such, it is currently unknown if these 
melanomas represent distinct molecular subgroups, have mutations in novel genes that 
activate the MAPK pathway or are susceptible to unique treatment strategies.  
 
Comprehensive genetic analysis including candidate gene sequencing, oncogene 
mutation profiling, SNP array and expression array analysis were combined to assess the 
overall pathways affected in a panel of 42 local lymph node metastatic melanoma cell 
lines. A small subset of cell lines did not exhibit mutations in either BRAF or NRAS. 
Unsupervised and supervised clustering of these BRAF/NRAS WT cell lines did not 
indicate that these cell lines were unique molecular entities and were likely to have 
constitutive MAPK activity.  To investigate the possibility of mutations occurring in novel 
genes that could activate the MAPK pathway, whole exome sequencing (WES) was 
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performed on 4 BRAF/NRAS WT cell lines (C022, C067, C077 and C084). This revealed a 
number of interesting mutation events, including 3 of 4 cell lines with nonsense mutations 
in NF1, a negative regulator of the MAPK pathway. NF1 has previously been shown to be 
susceptible to mTOR inhibition in leukaemia, possibly providing a novel therapeutic 
strategy for BRAF/NRAS WT cell lines with mutations in NF1.  
 
The results from this study highlight the benefits of overlaying multiple sets of data to 
identify genes involved in the development and progression of melanoma. In addition, this 
study demonstrates that key pathways are frequently mutated in melanoma and that 
mutations can occur in novel genes upstream or downstream of genes involved in these 
pathways. Lastly, next generation sequencing can comprehensively identify mutations 
occurring in tumours and will be a useful tool within the clinic in regards to personalised 
therapy in the future. 
 
4.2. Contribution of candidate 
 
Initial project design and planning was conducted with supervisors. The harvesting of DNA 
and RNA from the C series of metastatic melanoma cell lines used in this study was 
performed with the help of Lauren G. Aoude. I generated and analysed data produced 
from the SNP and expression arrays with the help of Mitchell S. Stark, Derek J. Nancarrow 
and Glen M. Boyle. I generated and analysed data from candidate gene sequencing and 
oncogenic profiling using OncoCarta and MelaCarta mutation panels. WES was performed 
by Macrogen (Korea); however I performed downstream bioinformatic analysis that also 
included Ingenuity pathway analysis. I compiled and wrote the manuscript.   
 
4.3. Acknowledgment of contribution of others 
 
The panel of C series stage III metastatic melanoma samples were collected by Michael 
O’Rourke and cell lines from these samples were established by Cathy Lanagan, Linda 
O’Connor and Christopher W. Schmidt. Lauren G. Aoude contributed to the generation of 
cell line stocks and the subsequent extraction of DNA/RNA. SNP array data generation 
and analysis was compiled under the guidance of Mitchell S. Stark and Derek J. 
Nancarrow, respectively. Glen M. Boyle assisted with the clustering analysis of the 
expression array results. Mitchell S. Stark, Michael G. Gartside, Lauren G. Aoude, 
Vanessa F. Bonazzi and Susan L. Woods contributed to the generation of WES 
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BRAF/NRAS mutant data mentioned within this report and will assist with validation and 
functional analysis that will be required for publication. All authors reviewed and supplied 
comments on the final manuscript.  
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Exome sequencing of wild-type BRAF and NRAS metastatic 
melanomas reveals novel mutations in known pathways of 
melanoma development 
 
Ken Dutton-Regester, Lauren G. Aoude, Mitchell S. Stark, Derek J. Nancarrow, Glen M. 
Boyle, Michael G. Gartside, Vanessa F. Bonazzi, Susan L. Woods, Cathy Lanagan, Linda 
O’Connor, Michael O’Rourke, Christopher W. Schmidt and  Nicholas K. Hayward.  
 
ABSTRACT 
Recent success with BRAF inhibitors in patients with BRAF V600E mutant metastatic 
melanoma has shifted extensive research efforts into this molecular subtype of the 
disease. However, patients with BRAF/NRAS wild type (WT) tumors, accounting for 
approximately 30% of patients, have not been extensively characterised.  To further 
investigate the genetic mechanisms behind this subtype of melanoma, comprehensive 
mutation analysis of 42 stage III metastatic melanoma cell lines was performed using a 
variety of high-throughput methodologies and subsequent pathway analysis. There was no 
association between BRAF/NRAS mutant cell lines and BRAF/NRAS WT cell lines based 
on unsupervised and supervised clustering of expression array data. To determine if 
mutations occurring in novel genes could alternatively explain the activation of the MAPK 
pathway, Whole-Exome Sequencing (WES) was performed on four BRAF/NRAS WT cell 
lines. Putatively inactivating somatic mutations were identified in multiple samples in NF1, 
PLCE1 and SGK1 and were mutually exclusive to BRAF/NRAS mutations. Interestingly, 
previous experiments have demonstrated these genes are potent negative regulators of 
the MAPK pathway; hence, mutational inactivation of this class of protein may represent a 
novel mechanism of MAPK pathway activation in BRAF/NRAS WT tumors. Lastly, WES of 
BRAF/NRAS WT cell lines identified a number of clinically actionable mutations, lending 
support to the application of next generation sequencing in the choice of treatment for 
cancer patients.  
 
INTRODUCTION 
Patients with late stage or disseminated melanoma, a cancer historically refractory to 
chemotherapeutic treatment, exhibit high rates of mortality, with a median life expectancy 
of 6 months. Recently, the approval of two new drugs, Ipilimumab and Vemurafenib 
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(PLX4032), has improved rates of progression-free and overall survival in patients with 
metastatic melanoma [1-3]. 
 
Ipilimumab, an anti-CTLA4 antibody, is designed to promote durable immune responses in 
patients by blocking the immune suppressing activity of CTLA4 on the surface of cytotoxic 
T cells [4].  Although Ipilimumab has demonstrated complete responses in patients and 
improved overall rates of survival, this drug can promote severe grade III and IV side 
effects leading to premature termination of therapy, and on rare occasions, treatment-
related mortalities [2]. As such, a number of challenges regarding the clinical management 
of Ipilimumab remain, and hopefully, with the identification of positive biomarkers of drug 
response, improvements in the clinical utility of this drug will occur.  
  
The other recently approved drug is Vemurafenib, a molecular based targeted drug that 
counteracts the effect of constitutive kinase signalling produced by mutations at valine 
coding position 600 in the gene BRAF.  Mutations of BRAF occur in 40-70% of cutaneous 
melanomas [5], the majority accounting for V600E alterations, which are the target of 
Vemurafenib [6]. Although Vemurafenib can rapidly reduce tumour mass and progression-
free survival, its long-term ability to significantly impact on overall survival has been limited 
by a multitude of tumour acquired resistance mechanisms [7-12]. Significant research 
efforts are currently underway in an attempt to reverse this trend, from investigations of the 
primary resistance mechanism to combination molecular drug therapies targeting the 
BRAF/MEK/ERK mitogen-activated kinase (MAPK) pathway. 
 
The MAPK pathway is one of the most frequently activated and investigated pathways in 
the development and progression of melanoma. Aside from approximately 50% of 
cutaneous melanomas exhibiting somatic mutations in BRAF, 20% have mutually 
exclusive mutations in NRAS, a gene upstream of BRAF mutation of which can also result 
in activation of the MAPK pathway [13]. Although BRAF and NRAS mutations account for 
up to 70% of melanomas, activation of the MAPK pathway and subsequent ERK 
phosphorylation is inherent to almost all melanoma tumors [14]. Currently, the remaining 
30% of melanomas that are BRAF/NRAS wild type (WT) have not yet been extensively 
characterised. This is of interest, as BRAF/NRAS WT melanomas may represent a unique 
molecular entity to BRAF/NRAS mutant melanomas, have mutations in novel genes that 
activate the MAPK pathway, or be susceptible to different therapeutic strategies.  
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Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) strategies 
have begun to shed light on the complexity of the ‘mutational landscape’ of cancer, 
including metastatic melanoma [15-18]. In particular, WES studies have led to the 
identification of a number of frequently mutated genes involved in melanomagenesis 
including GRIN2A [15], MAP3K5/MAP3K9 [16] and MAP2K1/MAP2K2 [17]. Notably, due 
to the high percentage of melanomas with BRAF/NRAS mutations and low number of 
samples sequenced, BRAF/NRAS WT melanomas have been under-represented in these 
WES studies. As such, important questions remain about the ‘mutational landscape’ of 
BRAF/NRAS WT melanomas and warrant unbiased mutation analysis provided by next 
generation sequencing technology.  
 
In order to address these disparities, comprehensive genetic analysis was performed on a 
panel of 42 local lymph node metastatic melanoma cell lines to identify a small subset of 
BRAF/NRAS WT melanomas. This subgroup of melanomas were then subjected to a 
variety of analytical methods including WES to determine if mutations in novel genes could 
be responsible for activation of the MAPK pathway and to potentially identify novel 
therapeutic targets in these melanomas.   
 
 
MATERIALS AND METHODS 
Cell line and patient tumors 
A panel of 42 stage III local lymph node metastatic melanoma cell lines were established 
with informed consent at the Queensland Institute of Medical Research as previously 
described [19]. Clinical information of these cell lines is included in Supplementary Table 
1. All cell lines with matching Lymphoblastoid Cell Lines (LCL) and available tumour 
sample were confirmed for authenticity using STR profiling analysis using an AmpFISTR 
Profiler Plus PCR amplification kit (Life Technologies) and analysed on a 3100 Genetic 
Analyzer (Life Technologies). Cell lines were cultured in filter-sterilized RPMI1640 
supplemented with 10% heat-inactivated foetal bovine serum (55°C for 30 minutes), 100 U 
ml-1 penicillin and 100 µg ml-1 streptomycin at 37°C (5% CO2). Cells were cultured at the 
lowest number of passages in order to obtain sufficient material for analysis. Samples 
were collected at an average of nine passages, at which point, cells were trypsinised and 
cell pellets washed in PBS before DNA or RNA extraction.  
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DNA/ RNA extraction and cDNA synthesis 
Cell line DNA was extracted using QIAamp Blood Maxi Kits (QIAGEN) according to the 
manufacturer’s instructions. For tumor DNA, 20-30 mg of fresh frozen tumor was extracted 
with QIAamp DNA mini kits (QIAGEN) on-column RNAse digestion. Tissue was pulverised 
in liquid nitrogen then incubated with ATL buffer (QIAGEN) and Proteinase K for 96 hoursr 
at 56°C. RNA from cell lines was extracted using RNeasy Mini Plus Kits (QIAGEN) from 
lysates isolated directly from culture flasks. Complementary DNA (cDNA) for sequencing 
was synthesized from 5 µg of RNA, random hexamers and superscript reverse 
transcriptase III (Invitrogen). 
 
Mutation analysis of genes previously implicated in melanoma 
Genes previously implicated in the development of melanoma were sequenced using 
cDNA via traditional capillary electrophoresis. Primer sequences and PCR conditions for 
TP53 [20], PTEN [21], RAC1 [22], MAP3K5 and MAP3K9 [16] were as previously 
described. Putative tumor suppressor genes involved in metastatic melanoma identified 
through candidate gene sequencing, TFG, ACTA2 and BMPR1A, were sequenced as 
detailed [19]. Mutations detected through capillary sequencing were confirmed as somatic 
using matched LCL and tumor samples, if available, to rule out mutations acquired during 
the process of cell culturing. Genes mutated in an oncogenic fashion (BRAF, NRAS, 
CDK4, ERBB4, PIK3CA, PTK2B, NEK10 and MET) were identified using MelaCarta v1.0 
(Sequenom, San Diego) and OncoCarta® v1.0 mutation panels on the Sequenom 
MassArray® platform [19].  
 
SNP array analysis  
39 of 42 stage III melanoma cell lines from the C series were analysed for chromosomal 
copy number gains and losses using Illumina HumanCNV370-Quad v3.0 Sentrix Bead 
arrays as described previously [23]. Data was analysed using Genome Studio V2009.1 
(Illumina) and an R script based on SiDCoN methodology [24]. Strong imbalanced 
amplification events representing at least 4 or more gains in autosomal chromosome were 
determined with a Log R ratio above 0.4 and a B-allele score above 0.58 (Supplementary 
Table 2). Homozygous deletions were identified using Log R ratios below -3 
(Supplementary Table 3).  
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Expression array analysis 
Complementary RNA (cRNA) was generated using Illumina TotalPrep RNA Amplification 
Kits (Ambion) and hybridised for 16 hours onto Illumina HumanHT-12 v3 Sentrix BeadChip 
arrays. Data was analysed and extracted using Genome Studio V2009.1 (Illumina) and 
imported into GeneSpring v11.5.1 (Agilent Technologies Inc.). Hierarchical clustering 
analysis (supervised and unsupervised) was performed using probes filtered by 
expression of genes using p ≤ 0.05 in 4 of 42 samples that varied with a standard 
deviation > 2 using a Pearson Centered Complete linkage algorithm. Supervised clustering 
was performed on BRAF or NRAS mutation status using a Mann-Whitney test to see 
where BRAF/NRAS WT cell lines were distributed. 
 
Whole-Exome Sequencing (WES) 
Cell lines selected for WES were sequenced and analysed by Macrogen (Korea) using 
Illumina TruSeq sample prep and sequencing chemistry according to Illumina protocols. 
Briefly, 1 µg of gDNA was fragmented by nebulisation, end repaired and ‘A’ tail ligated at 
the 3’ end of fragments. Illumina adaptors were then ligated and fragments size selected 
for 350-400 bp products before amplification and validation using the Agilent Bioanalyzer. 
DNA libraries were then hybridized to streptavidin exome capture beads, washed, 
hybridized a second time, eluted and amplified. Enriched libraries were then sequenced-
by-synthesis using an Illumina HiSeq 2000 according to Illumina Protocols. Sequencing 
data was extracted using CASAVA v1.7, aligned to the UCSC HG19 reference genome 
using BWA and variants detected using the SAMTOOLS suite of bioinformatic tools. A list 
of novel somatic mutations was generated through removal of variants within dbSNP131, 
dbSNP132 and HG1000 databases and overlapping variants within matched normal 
exome data. This list was then filtered using highly stringent criteria described previously 
[16] to reduce the number of potential false positives within the datasets. Single nucleotide 
mutations with a quality score above 100, had ≤ 10 reads of which ≤ 20% of reads were of 
the mutant allele, were deemed as robust mutations.  Insertion and deletion variants 
required quality scores ≤ 300 due to increased rates of false positives inherent to this type 
of analysis. 
 
Pathway Analysis 
Genes mutated in 3 or more samples that were assessed by WES were processed using 
Ingenuity software to identify genes involved in the MAPK pathway. Gene lists were 
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analysed for experimentally observed, direct and indirect interactions up to a distance of 2 
events to NRAS, BRAF, MEK and ERK.  
 
 
RESULTS AND DISCUSSION 
Pathway analysis identifies a subset of cell lines lacking mutations in MAPK 
pathway 
Comprehensive genetic analysis was performed on a panel of 42 local lymph node 
metastatic melanoma cell lines that included candidate gene sequencing, oncogene 
profiling, SNP array and expression array analysis. Mutations identified in these cell lines 
were grouped into biological relevant pathways, with a main focus on the four classical 
pathways of melanoma development (MAPK, PI3K, TP53 and RB1 pathways). Mutations 
occurred in NRAS and BRAF in 21% (9 of 42) and 57% (24 of 42) of cell lines, 
respectively; this resulted in approximately 80% (33 of 42) of cell lines exhibiting mutations 
within the MAPK pathway. There was no association between mutual exclusivity of 
mutations in the TP53 or RB pathways to BRAF or NRAS status. There was a small 
subgroup of samples that did not exhibit mutations within the MAPK pathway and were 
BRAF/NRAS WT (9 of 42 or ~20%). A summary of the pathways mutated in each cell line 
of the C series from the 4 main pathways to melanoma development can be seen in Table 
1. This data is expanded in Supplementary Table 4 that includes mutations in genes 
known to directly cause deregulation of pathways as well as genes that hypothetically may 
deregulate pathways.  
 
BRAF/NRAS WT cell lines do not cluster separately to BRAF/NRAS mutant cell lines 
according to expression array analysis 
Currently, BRAF/NRAS WT melanomas have not been extensively characterised and as 
such, may be unique molecular entities, have mutations in novel genes that activate the 
MAPK pathway, or be susceptible to different therapeutic strategies. To determine if 
BRAF/NRAS WT melanomas belong to a unique molecular subtype of melanoma, 
unsupervised and supervised clustering was performed on the C series using expression 
array data. Unsupervised clustering by probes and samples did not show any significant 
segregation based on BRAF/NRAS status or pathway specific mutation status (Figure 1). 
Supervised clustering based on NRAS and BRAF mutation status by probes and samples 
resulted in clear segregation of 2 groups indicative of their respective mutation status, as 
would be expected (Figure 2).  Interestingly, most BRAF/NRAS WT cell lines clustered 
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MAPK Pathway PI3K Pathway TP53 Pathway RB Pathway 
Sample Mutated Mutated Mutated Mutated 
C062 BRAF  PTEN  P14ARF  P16INK4A  
C002 NRAS  NRAS  P14ARF  P16INK4A  
C097 BRAF  PTEN  P14ARF  P16INK4A  
C071 BRAF  PTEN  P14ARF  P16INK4A  
C042 BRAF PTEN  P14ARF  P16INK4A  
C055 BRAF  PTEN  P14ARF  P16INK4A  
C001 NRAS  NRAS  TP53    
C100 BRAF  PIK3CA  TP53    
C083 NRAS  NRAS  TP53    
C044 BRAF  PTEN  TP53    
C038 BRAF  PTEN    P16INK4A  
C096 NRAS  NRAS    P16INK4A  
C091 BRAF  PTEN    P16INK4A  
C054 NRAS  NRAS    P16INK4A 
C057 BRAF  PTEN    CDK4  
C106 NRAS  NRAS      
C006 NRAS  NRAS      
C013 NRAS  NRAS      
C027 NRAS  NRAS      
C089 BRAF    P14ARF  P16INK4A  
C058 BRAF    P14ARF  P16INK4A  
C081 BRAF    P14ARF  P16INK4A  
C045 BRAF    TP53    
C060 BRAF    TP53    
C074 BRAF    TP53    
C065 BRAF    MDM2    
C004 BRAF        
C017 BRAF        
C088 BRAF        
C078 BRAF        
C094 BRAF        
C108 BRAF        
C011 BRAF        
C077*  [BRAF] ERBB4  TP53    
C021     TP53    
C084*      TP53    
C086     TP53    
C052       CCND1 
C067*        [RB1] 
C022*          
C025         
C037         
 
 
Table 1: Summary of pathways mutated in C series metastatic melanoma cell lines.   
Cell lines were analysed for mutations in key genes from 4 frequently deregulated pathways of melanoma 
development. 8 of 42 samples did not have mutations in the MAPK and PI3K pathway.   * Samples that were 
selected for Whole-Exome Sequencing (WES). Genes in parenthesis indicate mutations detected after WES.  
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RB 
Figure 1: Unsupervised clustering of the C series of metastatic melanoma cell 
lines shows no significant sub-grouping associated with mutation status.  
Data generated from Illumina HT12 expression arrays and clustered by probes and 
samples using GeneSpring X. Cell line name with mutation status is listed below the 
cluster plot based on BRAF (green), NRAS (red) or BRAF/NRAS WT (blue). Four 
pathways that are frequently deregulated in melanoma are also listed; solid blue 
squares indicate mutation of the pathway in the associated sample.  Metastatic 
melanoma cell lines did not segregate based on mutation or pathway analysis.  
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Figure 2: Supervised clustering based on BRAF and NRAS mutation status. 
Data generated from Illumina HT12 expression arrays and clustered by probes and 
samples using GeneSpring X. Cell line name with mutation status is listed below 
the cluster plot based on BRAF (green), NRAS (red) or BRAF/NRAS WT (blue). 
Four pathways that are frequently deregulated in melanoma are also listed; solid 
blue squares indicate mutation of the pathway in the associated sample.  
Supervised clustering based on NRAS or BRAF mutation status segregating into 2 
distinct entities. Interestingly, BRAF/NRAS WT cell lines segregated in between 
BRAF and NRAS groups but closer to the latter. These results indicated that 
BRAF/NRAS WT melanomas are likely to have MAPK pathway activation and this 
may be due to mutations in novel genes that interact with this paper.  
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predominately towards the NRAS mutant subgroup but adjacent to the BRAF mutant 
subgroup. These results appear to indicate that BRAF/NRAS WT cell lines are not unique 
molecular entities and are likely to have activation of the MAPK and PI3K pathways. This 
result is not surprising as it has been shown that the majority of melanomas exhibit 
constitutive MAPK activity, including melanomas that are BRAF/NRAS WT [14]. Based on 
these findings, BRAF/NRAS WT melanoma cell lines were analysed using WES to 
determine if these samples harboured mutations in novel genes interacting with the MAPK 
pathway. A strategy of the filtering process is demonstrated in Figure 3. 
 
Whole-Exome Sequencing (WES) of BRAF/NRAS WT cell lines 
To further investigate the mechanisms of mutations driving non MAPK pathway mutated 
tumors, four BRAF and NRAS Wild Type (WT) cell lines and their matching LCLs were 
subjected to WES using an Illumina Hi-Seq 2000. An average of 76,509,000 total reads of 
101 bp length was generated per sample resulting in a median read depth of 50X 
coverage of targeted regions. Comparison of variants called between WES and SNP array 
analysis indicated a rate of >99.5% concordance and false negative rate of <0.05%.  Strict 
filtering strategies previously established by our laboratory [16], were applied to the variant 
lists in order to reduce the rate of false positives without overly inflating the false negative 
rate. The accuracy of this approach was assessed by the comparison of 8 previously 
identified mutations against the list of mutations in the filtered WES lists (Supplementary 
Table 5). Four mutations were identified using the strict filtering criteria, three were present 
in the unfiltered mutation lists and one mutation was not detected at all. This disparity 
highlights the difficulties of next-generation sequencing analysis and can be the result of 
insufficient sequencing coverage, unsuccessful hybridisation of targeted captured regions 
or excessive stringency of filtering criteria. Although it is possible putative driver mutations 
may be missed, the strict filtering criteria was applied to the WES data sets to reduce false 
positives in light of the high rate of mutation inherent to cutaneous melanoma due to UV 
exposure [25].  
 
A total of 8859 somatic mutations were detected (range per sample: 378-3873) that 
included 5714 Non-Synonymous (NS) mutations and 3036 Synonymous (S) mutations 
(Supplementary Table 5 and 6). Consistent with previous melanoma exome reports [15-
17], the NS:S ratio was 1.88, not higher than the predicted NS:S ratio of 2.5 for non-
selected passenger mutations [26]. A number of mutations occurring in key melanoma-
associated genes were identified, including ADAM29 [27], ADAMTS18 [28], GRIN2A [15], 
115
F
ig
u
re
 3
: 
F
il
te
ri
n
g
 s
tr
a
te
g
y
 t
o
 i
d
e
n
ti
fy
 n
o
v
e
l 
g
e
n
e
s
 o
f 
in
te
re
s
t 
in
 B
R
A
F
/N
R
A
S
 W
T
 c
e
ll
 l
in
e
s
 i
n
v
o
lv
e
d
 i
n
 t
h
e
 M
A
P
K
 p
a
th
w
a
y
. 
 
Su
pe
rv
is
ed
 a
nd
 u
ns
up
er
vi
se
d 
cl
us
te
rin
g 
an
al
ys
is
 o
f 
ex
pr
es
si
on
 a
rr
ay
 d
at
a 
in
di
ca
te
d 
th
at
 B
R
A
F
/N
R
A
S
 W
T 
ce
ll 
lin
es
 d
id
 n
ot
 s
eg
re
ga
te
 
se
pa
ra
te
ly
 to
 B
R
A
F
/N
R
A
S
 m
ut
an
t c
el
l l
in
es
. T
o 
in
ve
st
ig
at
e 
if 
m
ut
ua
l e
xc
lu
si
ve
 m
ut
at
io
ns
 o
cc
ur
re
d 
in
 n
ov
el
 g
en
es
 c
om
pa
re
d 
to
 B
R
A
F
 a
nd
 
N
R
A
S
 m
ut
an
t c
el
l l
in
es
, 4
 o
f 9
 B
R
A
F
/N
R
A
S
 W
T 
ce
ll 
lin
es
 w
er
e 
W
ho
le
-E
xo
m
e 
Se
qu
en
ce
d 
(W
ES
). 
A 
to
ta
l o
f 2
2 
ge
ne
s 
in
te
ra
ct
in
g 
w
ith
 th
e 
M
AP
K 
pa
th
w
ay
 w
er
e 
id
en
tif
ie
d 
th
at
 w
er
e 
m
ut
at
ed
 ≥
3 
sa
m
pl
es
 th
at
 w
er
e 
W
ES
. 
 
116
TRRAP [15], PTPRD [29], MAP3K5 and MAP3K9 [16] (Supplementary Table 7). 
Interestingly, mutations were detected in key genes of the MAPK and RB pathways 
including a BRAF S467L mutation in C077 and RB1 E209K mutation in C067. Although 
BRAF mutation status was assessed using the MelaCarta and OncoCarta mutation 
panels, these panels only assess the top 26 mutations that are frequently mutated in 
melanoma. The BRAF S467L mutation has only once been previously identified in a 
Superficial Spreading Melanoma (SSM) [30], highlighting the potential of missing rare 
variants using the above mentioned mutation panels. RB1 is rarely mutated in melanoma 
and hence was not sequenced to assess the mutation status in the C series melanoma 
cell lines. Regardless, the RB1 E209K mutation appears to be patient specific and is not 
present within the Catalogue of Somatic Mutations in Cancer (COSMIC) database [31].  
Although not experimentally determined, it is interesting to speculate whether the BRAF 
S467L or RB1 E209K mutations are responsible for activating or inactivating the MAPK 
and RB pathways respectively in these cell lines. 
 
Recurrent or ‘Hotspot’ Mutations 
Oncogenic or activating mutations, such as those occurring within BRAF, are frequently 
associated with recurrent or ‘hotspot’ mutations located within critical functional residues of 
genes. A total of 13 recurrent mutations were identified occurring in 2 of 4 cell lines used 
for WES (Supplementary Table 8). Although none of the genes included in this list encode 
kinases, recurrent mutations in interesting genes included POLQ (H2341Y) and IL7R 
(R206X) that were mutated in C077 and C084.  
 
POLQ is a DNA polymerase whose functional in vivo role is not clearly understood 
although it may have a role in base excision repair [32] and double strand break repair 
[33]. POLQ has been implicated in cancer and is over-expressed in colorectal [34] and 
breast cancer [35] and is associated with poor prognosis and worse clinical outcomes. 
Ectopic overexpression of POLQ in breast cancer cell lines resulted in defective DNA fork 
replication causing chromosomal damage suggesting a role in genetic instability [36]. 
Notably, both C077 and C084 who have POLQ H2341Y mutations, exhibit a ~10-fold 
higher rate of mutation (over 3000 mutations per sample) compared to average rates of 
mutation in melanoma (300-500 mutations) [15, 16]. This H2341Y mutation occurs within 
an evolutionary conserved residue of the DNA polymerase motif hence mutation may 
affect correct protein function resulting in genomic instability in these samples. Genome 
instability resulting in increased rates of mutation has been demonstrated previously in 
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Sample ID Gene Coding Change Protein Change Function 
C084 ALK G4591A G1531S Receptor Tyrosine Kinase 
C084 ALK G4508A W1503X Receptor Tyrosine Kinase 
C022 ATF2 C272T T91I Transcription Factor 
C077 ATF6 C1462T H488Y Transcription Factor 
C084 BRCA2 C2161T P721S DNA Damage and Repair 
C084 DICER1 G1195A E399K RNA Processing 
C077 DICER1 C1835T P612L RNA Processing 
C077 DICER1 C2716T R906C RNA Processing 
C067 DOCK2 G367A D123N Actin remodelling and migration 
C077 DOCK2 G375A M125I Actin remodelling and migration 
C084 DOCK2 C653T S218F Actin remodelling and migration 
C077 DROSHA T1343G F448C RNA Processing 
C084 DROSHA C2965T P989S RNA Processing 
C067 EGF G2941A D981N Receptor Tyrosine Kinase 
C077 EGF C2654T S885F Receptor Tyrosine Kinase 
C067 EGFR C584T P195L Receptor Tyrosine Kinase 
C077 EGFR C2491T R831C Receptor Tyrosine Kinase 
C077 EGFR C2819T T940I Receptor Tyrosine Kinase 
C084 ERBB2 T2317C Y773H Receptor Tyrosine Kinase 
C077 ERBB3 C2579T P860L Receptor Tyrosine Kinase 
C084 ERBB3 C2867T P956L Receptor Tyrosine Kinase 
C084 EZH2 G1030T E344X Histone/ Chromatin Modification 
C067 HDAC9 G2158A D720N Histone/ Chromatin Modification 
C077 HDAC9 A1085T K362I Histone/ Chromatin Modification 
C084 HDAC9 C2678T T893I Histone/ Chromatin Modification 
C084 MAP3K15 G748A D250N Apoptosis 
C084 MAP3K4 C2887T Q963X Apoptosis 
C084 MAP3K4 C4646T S1549L Apoptosis 
C077 MAP4K3 C1295T P432L Apoptosis 
C077 MAP4K3 C1702T P568S Apoptosis 
C077 MAP4K5 G1427A R476Q Apoptosis 
C067 MAPK10 C811T P271S Apoptosis 
C084 MRAS C91T H31Y RAS/ GTPase signalling 
C067 NEK11 C361T Q121X Kinase 
C084 NEK5 C688T R230C Kinase 
C077 NEK5 C739T R247X Kinase 
C077 NF1 C3163T Q1055X RAS signalling 
C067 NF1 C3520T Q1174X RAS signalling 
C077 NF1 C4108T Q1370X RAS signalling 
C084 NF1 C7486T R2496X RAS signalling 
C077 NOTCH1 C2333T T778I Growth signalling and Invasion 
C067 NOTCH2 17_18del 6_6del_fs Growth signalling and Invasion 
C084 NOTCH2 C4003T P1335S Growth signalling and Invasion 
C067 NOTCH2 C611T S204F Growth signalling and Invasion 
C077 NOTCH3 G3607A E1203K Growth signalling and Invasion 
C084 NOTCH3 G4414A E1472K Growth signalling and Invasion 
C084 NOTCH3 C3446T P1149L Growth signalling and Invasion 
C077 PIK3C2A C4225A L1409I Cell Proliferation and survival 
C077 PLCE1 G4870T D1624Y Cell Proliferation and differentiation 
C077 PLCE1 C1017A F339L Cell Proliferation and differentiation 
C084 PLCE1 G500A G167E Cell Proliferation and differentiation 
C022 PLCE1 C3644T P1215L Cell Proliferation and differentiation 
C084 PLCE1 G3560A R1187Q Cell Proliferation and differentiation 
C084 RET C2012T S671L Receptor Tyrosine Kinase 
C084 RHO G364A E122K Receptor Tyrosine Kinase 
C077 SETDB1 C1483T R495X Histone/ Chromatin Modification 
C077 SGK1 C358T P120S Serine/ Threonine Kinase 
C084 SGK1 C1489T P497S Serine/ Threonine Kinase 
C067 SGK1 A37G T13A Serine/ Threonine Kinase 
C022 SMARCA2 C92T P31L Histone/ Chromatin Modification 
C084 TET1 G4606A E1536K Methylation 
C084 TET2 G3385A D1129N Methylation 
C084 TET2 G5767A E1923K Methylation 
C084 TET2 G4845A M1615I Methylation 
C084 TP63 G1517A G506D DNA Damage and Repair 
C084 TP63 G366A M122I DNA Damage and Repair 
C077 TP63 C1447T R483X DNA Damage and Repair 
C067 TP63 T602C V201A DNA Damage and Repair 
 
 
Table 2: Somatic mutations occurring in genes previously implicated in cancer in BRAF/NRAS WT 
cell lines. Four samples were Whole-Exome Sequenced (WES) to identify novel genes involved in this 
subset of patients. A number of genes implicated in a range of important cellular processes that have 
previously been associated with cancer were mutated. Bold indicates homozygous mutations. 
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colorectal cancer with 8X more somatic non-synonymous mutations in microsatellite 
unstable cancers than microsatellite stable cancers [37].   
 
The Interleukin 7 receptor (IL7R) has a number of roles in lymphocyte development, 
immune response, and chromatin modification [38]. Although somatic activating mutations 
have been identified in IL7R in acute lymphoblastic leukaemia [39, 40], the recurrent 
mutation identified in this study, in contrast, suggests inactivation by premature termination 
through nonsense mutation. Recently, low transcriptional expression of IL7R has been 
associated with familial longevity [41] while downregulation of IL7R resulted in decreased 
histone acetylation ability in thymocytes [42]. Mechanisms of longevity and chromatin 
modification are often intricately linked to processes of human ageing and cancer [43] and 
hence warrant further investigation. 
 
Mutations in genes previously implicated in cancer 
A number of genes mutated in the WES BRAF/NRAS WT samples have functional roles 
with previous associations to the development and progression of cancer (Table 2). This 
included genes involved in transcription and chromatin modification, apoptosis, cellular 
proliferation, differentiation, DNA damage repair and RNA processing.  C077 and C084 
had multiple mutations occurring in DICER1 and DROSHA, key proteins involved in 
miRNA processing, regulation and maturation. DICER1 mutations have been recently 
identified in 30 of 102 (29%) non-epithelial ovarian cancers, however mutation did not 
abolish functional activity but rather altered RNA processing in a cell context manner [44]. 
The potential dual-hit inactivation of these genes would suggest the inability of these cell 
lines to modulate gene expression with miRNA mechanisms produced within the cell.  
 
Frequent mutations also appear in genes involved in histone and chromatin modification 
including a P31L mutation in SMARCA2 and 3 of 4 samples harbouring Histone 
Deacetylase 9 (HDAC9) mutations. SNP array analysis has previously revealed 
homozygous deletions of SMARCA2 and an alternate histone deacetylase family member 
of HDAC4 in metastatic melanoma cell lines [23, 45]. A nonsense mutation was also 
detected in EZH2, a gene with frequent inactivation mutations in acute lymphoblastic 
leukaemia [46], while multiple mutations were detected in TET1 and TET2 which have 
been linked to myeloid malignancies [47].  Lastly, a nonsense mutation was identified in 
SETDB1 in C077; this gene has recently been found to act in an oncogenic fashion in 
cooperation with BRAF V600E mutation [48].  
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Figure 4: Novel somatically mutated genes that may be involved in the MAPK 
pathway in BRAF/NRAS WT cell lines. 
A). Novel mutated genes (NF1, PLCE1 and SGK1) in BRAF/NRAS WT cell lines 
interacting with the MAPK pathway. Solid connections between genes indicate 
experimentally observed direct interactions while dotted lines indirect interactions.  
B). Mutations status of NF1, PLCE1 and SGK1 in 4 BRAF/NRAS WT cell lines that 
were WES. None of the genes were mutated in 10 BRAF/NRAS mutant cell lines that 
have been previously WES (unpublished and published data) indicating mutual 
exclusivity.  
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 Novel mutated genes potentially regulating MAPK pathway activity  
Genes that are recurrently mutated across numerous samples can indicate functional 
importance and be used as a filtering strategy for identifying genes involved in cancer 
development. Using this approach, 114 genes were mutated in at least 3 of the 4 cell lines 
that were screened using WES, of which 6 genes were mutated in all 4 cell lines 
(Supplementary Table 9). Next generation sequencing approaches can result in the 
generation of false positive mutations by misalignment caused by technological limitations 
associated with alignment methodologies and short read lengths. This can be problematic 
for sequences in repetitive regions, pseudogenes, and members pertaining to gene 
families sharing conserved regions of sequence. As such, it is likely that the 6 genes 
mutated in all cell lines are a result of alignment error rather than bona-fide recurrently 
mutated genes. For this reason we focused on recurrently mutated genes that occurred in 
3 of 4 cell lines that were whole exome sequenced.  
  
Since BRAF/NRAS WT cell lines did not group separately through unsupervised clustering 
analysis, and in light of constitutive MAPK activity through ERK phosphorylation in this 
molecular entity [14], Ingenuity Pathway Analysis (IPA) was used to identify novel genes 
that may be responsible for MAPK pathway activation from the list of recurrently mutated 
genes. Using search criteria of direct and indirect experimentally observed interactions to 
RAS/BRAF/MEK/ERK, IPA revealed a total of 22 genes interacting with the MAPK 
pathway. To filter this list further, we used existing WES data from 10 metastatic 
melanoma cell lines (published [16] and unpublished) to identify recurrently mutated genes 
that were mutually exclusive, and not mutated in BRAF/NRAS mutant melanomas 
(Supplementary Table 9). This process identified SGK1, PLCE1 and NF1 that are 
recurrently mutated genes, mutually exclusive to BRAF/NRAS mutant melanomas that 
also interact with members of the MAPK pathway (Figure 4).    
 
Serum/Glucocorticoid Regulated Kinase 1 (SGK1) is a serine/threonine kinase implicated 
in cellular stress responses and cell survival through a variety of molecular pathways [49]. 
Reports into the mechanism of action of SGK1 are hotly debated with evidence suggesting 
that either SGK1 activation or inactivation can lead to tumorigenesis; however this 
disparity is likely to be explained by the context of tissue in question. In regards to SGK1 
activation promoting tumorigenesis, SGK1 can activate MDM2-dependent TP53 
ubiquitylation [49], can stabilise MDM2 through the mTOR pathway [50],  and can directly 
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interact and activate ERK1/2 and MEK1/2 in hepatocytes [51]. However, the mutations 
detected in SGK1 from the BRAF/NRAS WT cell lines present in a typical tumor 
suppressor fashion and are spread throughout the entire length of the gene; this suggests 
that mutations of SGK1 may rather be inactivating in melanoma but will require functional 
validation. Supporting this notion, SGK1 has been shown to be a potent negative regulator 
of BRAF through phosphorylation of Ser 364 [52]. SGK1 has high constitutive expression 
across the C series of metastatic melanoma cell lines (probe ILMN-1702487), possibly 
indicating a negative feedback loop imposed in melanocytes to control the MAPK pathway. 
Hypothetically, this mechanism could be overridden by either NRAS or BRAF mutation 
resulting in auto-phosphorylation, or alternatively, inactivating mutations in SGK observed 
in BRAF/NRAS WT cell lines.  
 
Phospholipase C, epsilon 1 (PLCE1) catalyses the hydrolysis of phosphotidylinositol (PI)-
4,5-bisphosphate generating messengers involved in cell growth, differentiation and gene 
expression [53].  PLCE1 is a putative tumor suppressor gene transcriptionally 
downregulated in colorectal cancer [54, 55] and is a novel susceptibility locus for 
esophageal squamous cell carcinoma [56, 57]. The biological function of PLCE1 is 
complicated due to the various catalytic and binding domains located throughout the 
protein. Both RasGEF and PI-PLC domains within PLCE1 can activate the MAPK pathway 
but via different mechanisms [53]. Since both domains can activate the MAPK pathway, a 
H1144L mutant abolishing PI hydrolysis by the PI-PLC domain in PLCE1 was tested in 
conjunction with WT PLCE1. Interestingly, both versions promoted MAPK activity, however 
this effect was increased in H1144L mutant PLCE1 compared to WT suggesting that PI 
hydrolysis activity, as is present in WT PLCE, can act in a regulatory negative feedback 
loop. Accordingly, if the mutations observed in BRAF/NRAS WT cell lines mimicked the 
effect of the H1144L mutation resulting in decreased PI hydrolysis, these mutations could 
explain increased activation of RAS and MAPK activity in these cell lines.  
 
Neurofibromin 1 (NF1) functions as a negative regulator of RAS via GTPase activity and 
mutations in this gene are associated with neurofibromatosis 1, a tumour predisposition 
syndrome [58, 59]. Patients with neurofibromatosis most frequently develop subcutaneous 
neurofibromas but also exhibit a range of hyper-pigmentary lesions in childhood [60] 
linking the disease to deregulation of pigmentation pathways [61]. Furthermore, the 
association between melanoma and neurofibroma originating from neural crest cells 
suggested that NF1 may have an important role in melanoma development, but a strong 
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correlation has remained elusive [62].  A number of clinical case reports have identified the 
involvement of NF1 in melanoma [63, 64] but only 0.5%-5% of neurofibromatosis patients 
are subsequently diagnosed with this tumour.  
 
A number of early reports investigated the mutation of NF1 in sporadic cutaneous 
metastatic melanoma [65, 66]. These studies revealed a small proportion of melanoma cell 
lines had homozygous or hemizygous deletions of NF1 but did not assess whether point 
mutations occurred using traditional sequencing approaches.  Similarly, analysis of NF1 in 
uveal melanoma revealed 18 of 38 (47%) of samples with weak expression of NF1 and 
identified a homozygous deletion in one sample [67]. Surprisingly, WES of BRAF/NRAS 
WT melanomas revealed 3 of 4 cell lines with nonsense mutations in NF1, while no 
mutations were detected in BRAF/NRAS mutant cell lines. This finding is interesting due to 
the previously documented role of NF1 as a negative regulator of RAS and that NF1 
mutation is mutually exclusive to BRAF or NRAS mutation. Further support of this notion is 
a high rate of NF1 loss in desmoplastic melanoma, for which BRAF mutations have not 
been documented [68],  compared to common melanomas (10/15 or 67% to 1/20 or 5% 
respectively) [69].  
 
Mutation of NF1 has been detected in numerous cancers including ovarian [70], 
glioblastoma multiforme [71], juvenile myelomonocytic leukaemia (JMML) [72] and Adult 
Acute Myeloid Leukaemia (AAML) [73]. A number of mutations affecting RAS pathways 
have been documented in JMML and  consistent with our observations, NF1 mutations are 
nearly always mutually exclusive to NRAS and KRAS mutations [72]. More importantly, the 
recent identification of NF1 inactivation in AAML demonstrated that NF1 does negatively 
regulate NRAS, and that essentially, NF1 inactivation results in a similar phenotype to 
oncogenic mutant NRAS [74].  Furthermore, cell lines with loss of NF1 functional activity 
displayed a reliance on mammalian target of rapamycin (mTOR) signalling and were 
sensitive to rapamycin-induced apoptosis. If these results were replicated in NF1 mutant 
metastatic melanomas, these findings would have a critical impact for patients with 
BRAF/NRAS WT tumors, a clinical entity that currently lacks any targeted treatment 
strategies. 
 
Potential therapeutic avenues in BRAF/NRAS WT cell lines 
Performing WES analysis in BRAF/NRAS WT metastatic melanoma cell lines provides the 
opportunity to retrospectively investigate mutations within these samples that may be 
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Cell Line Gene Mutation Therapeutic Avenue Drug 
C021 None None Alternative approach Ipilimumab 
C022* None None Alternative approach Ipilimumab 
C025 TFG P199S/ P361L MEK inhibitor? GSK112012/ AZD6244 
 
NEK10 E379K MEK inhibitor? GSK112012/ AZD6244 
 
None None Alternative approach Ipilimumab 
C037 None None Alternative approach Ipilimumab 
C052 CCND1 Amplification CDK4 inhibitor? UCN-01 
 
None None Alternative approach Ipilimumab 
C067* EGFR P195L ERBB inhibitor Lapatinib 
 
MRAS Amplification MEK inhibitor/ PI3K inhibitor? GSK112012/ AZD6244 
 
NF1 Q1174X mTOR inhibitor Rapamycin 
C077* BRAF S467L MEK inhibitor GSK112012/ AZD6244 
 
ERBB4 E452K ERBB inhibitor Lapatinib 
 
EGFR R831C/ T940I ERBB inhibitor Lapatinib 
 
NF1 Q1055X/ Q1370X mTOR inhibitor Rapamycin 
C084* BRCA2 P721S PARP inhibitor Veliparib (ABT-888) 
 
ERBB2 Y773H ERBB inhibitor Lapatinib 
 
NF1 R2496X mTOR inhibitor Rapamycin 
C086 TFG P380L MEK inhibitor? GSK112012/ AZD6244 
 
None None Alternative approach Ipilimumab 
 
 
Table 3: Potential therapeutic strategies for BRAF/NRAS WT patients. 
Whole-Exome Sequencing (WES) revealed mutations potentially susceptible to current therapeutic avenues 
in 3 of 4 patients. The remaining BRAF/NRAS WT samples assessed through traditional analytical methods 
did not reveal definitive therapeutic strategies indicating the potential benefits of next generation sequencing 
in the treatment of cancer. * Samples that were selected for WES. 
 
 
 
 
 
 
 
 
 
124
susceptible to novel or existing drug therapies. A summary of potentially relevant 
mutations and appropriate drug strategies are listed in Table 3.  
 
WES revealed mutations in the ERBB family of proteins, including EGFR, ERBB2 and 
ERBB4, in 3 of the 4 samples sequenced. It has been previously documented that 
approximately 19% of metastatic melanomas have mutations in ERBB4, resulting in 
increased kinase activity and transformation ability of melanoma cell lines in vitro [75]. In 
addition, it was demonstrated that use of a pan-ERBB pharmacological inhibitor, Lapatinib, 
reduced rates of proliferation while increasing apoptosis in ERBB4 mutant cell lines 
compared to counterpart wild-type ERBB4 cell lines [75]. One of the mutations validated in 
the ERBB4 study was E452K, the exact mutation identified in C077 from this study, 
suggesting that use of Lapatinib may have been an effective treatment strategy in this 
patient. Similarly, mutation of EGFR and ERBB2 can result in oncogenic activation as 
frequently observed in lung cancer [76]; however, mutations in EGFR and ERBB2 in this 
study are either rare or patient specific [31].  It is possible that ERBB inhibitors may 
represent an effective approach in these patients but would require functional validation.  
 
A number of mutations detected in BRAF/NRAS WT cell lines may also be susceptible to 
inhibitors of the MAPK pathway, or more specifically, inhibitors of MEK.  As mentioned 
previously, a rare S467L mutation was detected in BRAF using WES that was not detected 
through oncogenic profiling. Although this mutation is unlikely to be susceptible to current 
RAF inhibitors such as Vemurafenib [77], this mutation, if responsible for oncogenic 
activation of the MAPK pathway, may be susceptible to downstream inhibition using MEK 
inhibitors [78]. Alternatively, mutations were also identified in TFG in C025 and C086, a 
gene that has been shown to activate the MAPK and NFκB pathways [79] and are mutated 
in 5% of metastatic melanomas [23]. Although speculative without biological validation, it is 
possible these mutations may also be susceptible to MAPK pathway inhibition.  
 
Another interesting mutation revealed using WES was a BRCA2 P721S mutation in C084. 
BRCA2, in conjunction with BRCA1, is involved in double-strand DNA break repair through 
homologous recombination and base-excision repair pathways and is frequently mutated 
in sporadic and familial breast and ovarian cancer [70, 80]. Tumours with BRCA1/2 
mutations have insufficient DNA repair mechanisms and are susceptible to poly ADP 
ribose polymerase (PARP) inhibition in combination with chemotherapeutic agents, or as a 
mono-therapeutic approach, and have shown responses in preclinical melanoma xenograft 
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models [81-83]. Although recent clinical trials of PARP inhibition with temozolomide [84] 
and dacarbazine [85] have been tolerable, patient responses have been less than 
enthusiastic with no improvement observed in cohort of chemo-naive melanoma patients. 
It is interesting to speculate about the possibility of increased efficacy of PARP inhibition in 
BRCA1/2 mutant melanoma patients such as observed in C084; albeit realistically, this will 
be a small population of patients diagnosed with metastatic melanoma due to the low rates 
of BRCA1/2 mutation in this disease.  
 
SNP array analysis revealed a small number of amplification events that may be amenable 
to molecularly targeted therapies. C052 exhibited amplification of CCND1, a regulatory 
subunit of CDK4/6 subunit that interacts with RB1 and hypothetically might be susceptible 
to CDK4 inhibitors [86, 87].  Conversely, C067 harboured an amplification of MRAS, a 
reciprocal member of the RAS family of small GTPases of which NRAS is frequently 
mutated in melanoma. Although not investigated, MRAS amplification may be responsible 
for activation of the MAPK and PI3K pathways for which inhibitors of this pathway may be 
a rational approach to therapy [88]. 
 
Aside from the above mentioned amplifications, comprehensive genetic analysis of 
candidate gene sequencing, oncogene profiling and SNP array analysis, revealed minimal 
putative therapeutic targets in BRAF/NRAS WT cell lines.  Of the 6 cell lines that were not 
screened with WES and hypothetical strategies aside, no conclusive therapeutic strategies 
were presented from the data that was generated from traditional genetic analysis. This is 
in contrast to WES of BRAF/NRAS WT cell lines for which viable therapeutic targets were 
identified in 3 of 4 cell lines. This notion further supports the viability of next generation 
sequencing within the clinic as a personalised therapeutic approach, and although a 
number of important issues in its application remain, steps toward this approach have 
already begun to be implemented [89]. Lastly, for patients where therapeutic targets are 
not identified through comprehensive genomic analysis, immunological approaches such 
as Ipilimumab would most likely represent ideal treatment strategies.  
 
CONCLUSIONS 
 A comprehensive genetic analysis was performed on a panel of 42 stage III local lymph 
node metastatic melanoma cell lines in order to reveal deregulated pathways in 
melanomagenesis. Several mutations occurred in 4 main pathways of melanoma 
development; however, 9 of 42 cell lines did not demonstrate any known activating 
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mutation events in the MAPK pathway. These BRAF/NRAS WT cell lines did not 
segregate independently to BRAF/NRAS mutant melanomas upon supervised or 
unsupervised clustering using expression array data.  As nearly all melanomas exhibit 
constitutive activation of the MAPK pathway, clustering analysis suggested that mutation 
of novel genes linking into the MAPK pathway may explain the activation of this pathway. 
As such, WES of 4 BRAF/NRAS WT cell lines revealed a number of novel mutated genes 
including SGK1, PLCE1 and NF1. Mutations in NF1 are particularly interesting as they are 
mutually exclusive to BRAF/NRAS mutations and may be susceptible to inhibition through 
rapamycin.  Lastly, WES revealed a number of potential therapeutic avenues for 
BRAF/NRAS WT melanomas, a distinct molecular entity that currently has no 
recommended treatment strategy, and further supports the notion of next generation 
sequencing within a clinical setting. These findings warrant further functional validation and 
investigation. 
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Supplementary Table 9: Genes recurrently mutated in WES
List of genes that are mutated in either 4 samples or 3 samples that were Whole Exome Sequenced (WES)
This list of genes was compared against a set of 10 BRAF/NRAS mutated samples that were also WES 
(Stark 2012 Nature Genetics and unpublished data). Genes mutated in 3 samples were analysed using Ingenuity 
Direct relationship indicates exprimentally observed interaction, indirect indicates upstream/downstream genes
Genes mutated  in all 4 samples
Gene Accesion Number Mutated in BRAF/NRAS 
samples
CSMD1 NM_033225 2
MUC16 NM_024690 3
MUC4 NM_018406 0
MXRA5 NM_015419 4
PKHD1 NM_170724 5
ZNF536 NM_014717 0
Genes mutated in 3 samples
Gene Accesion Number Mutated in BRAF/NRAS samples
Ingenuity analysis MAPK 
pathway Relationship
A2M NM_000014 0 RAS/ BRAF/ MEK/ ERK Indirect
ABCC6 NM_001171 2
ACAN NM_001135 0 RAS/ BRAF/MEK/ ERK Indirect
ACSM2B NM_001105069 1
ADAMTS20 NM_025003 2
ADAMTS6 NM_197941 0
AKNA NM_030767 1
ANK3 NM_020987 0 BRAF/ ERK Indirect
ANKRD30A NM_052997 0
APOB NM_000384 4 RAS/ BRAF/ ERK Indirect
ARID1B NM_017519 1 RAS/ BRAF/ ERK Indirect
ARMC4 NM_018076 3
ARPP21 NM_016300 1
BRWD3 NM_153252 0
CCDC147 NM_001008723 0
CHD5 NM_015557 0
CMYA5 NM_153610 0
CNGB3 NM_019098 0
CNTNAP2 NM_014141 1
CNTNAP3 NM_033655 0
CNTNAP4 NM_138994 1
COL21A1 NM_030820 0
COL3A1 NM_000090 0 RAS Indirect
COL7A1 NM_000094 1
CSMD1 NM_033225 2
CSMD1 NM_033225 2
CSMD2 NM_052896 2
CSMD3 NM_052900 2
CUBN NM_001081 0
CXorf30 NM_001098843 0
DIP2B NM_173602 0
DNAH3 NM_017539 5
DNAH5 NM_001369 9
DNAH7 NM_018897 1
DOCK11 NM_144658 0 RAS/ BRAF/ MEK Indirect
DOCK2 NM_004946 1 RAC Indirect
DPYD NM_000110 3
DSCAM NM_001389 2
EGFLAM NM_001205301 0
EYS NM_198283 0
F8 NM_000132 1
FAM154A NM_153707 0
FBN3 NM_032447 4
FNDC1 NM_032532 0
FRAS1 NM_025074 0
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Gene Accesion Number Mutated in BRAF/NRAS samples
Ingenuity analysis MAPK 
pathway Relationship
GPR98 NM_032119 0
HDAC9 NM_001204147 1 RAS/ BRAF/MEK/ ERK Indirect
HEATR7B2 NM_173489 0
IGSF10 NM_178822 2
KALRN NM_001024660 2
KLHL4 NM_057162 1 ERK Indirect
LCT NM_002299 1
LPA NM_005577 0 RAS Indirect
LPHN2 NM_012302 0
LRP1B NM_018557 9
MAGEC1 NM_005462 2
ME1 NM_002395 0
MGAM NM_004668 1
MOV10L1 NM_001164104 2
MRGPRX2 NM_054030 0
MUC16 NM_024690 3
MUC4 NM_018406 0 RAS/ BRAF/ MEK/ ERK Indirect
MXRA5 NM_015419 4
MXRA5 NM_015419 4
MYH1 NM_005963 1
MYH7 NM_000257 0
MYO18B NM_032608 0
MYOM2 NM_003970 0
NCKAP5 NM_207481 0
NEB NM_001164507 0
NF1 NM_000267 0 RAS/ BRAF/ MEK/ ERK Indirect
NLRP2 NM_001174083 0 RAS/ BRAF/ ERK Indirect
NLRP9 NM_176820 1
ODZ1 NM_014253 4
OR5AR1 NM_001004730 0
PAPPA2 NM_020318 0
PCNXL2 NM_014801 0
PIPOX NM_016518 0 ERK Indirect
PKHD1 NM_170724 5
PLCE1 NM_001165979 0 RAS/ BRAF Indirect
PLCH1 NM_001130960 0
PLXDC2 NM_032812 0
PRICKLE1 NM_001144883 0 RAS/ BRAF/ MEK/ ERK Indirect
PZP NM_002864 0
RAG1 NM_000448 1
ROS1 NM_002944 0
SCN10A NM_006514 3
SCN4A NM_000334 0
SCN8A NM_014191 0
SCN9A NM_002977 0
SFXN2 NM_178858 0
SGK1 NM_001143676 0 BRAF Direct
SH2B1 NM_015503 0 BRAF Indirect
SIK3 NM_025164 1
SPEG NM_005876 0
SVEP1 NM_153366 0
SYNE1 NM_033071 4
TMPRSS11A NM_182606 0
TP63 NM_001114979 1 RAS/ BRAF/ ERK Indirect
TTN NM_133378 8
UNC5D NM_080872 1
USH2A NM_206933 4
YLPM1 NM_019589 0 RAS/ BRAF/ ERK Indirect
ZFHX4 NM_024721 0
ZFPM2 NM_012082 0
ZNF536 NM_014717 0
ZNF536 NM_014717 0
ZNF638 NM_014497 0 BRAF Indirect
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Chapter 5 
 
A high throughput panel for identifying clinically-relevant mutation 
profiles in melanoma  
 
Ken Dutton-Regester, Darryl Irwin, Priscilla Hunt, Lauren G. Aoude, Varsha Tembe, 
Gulietta M. Pupo, Cathy Lanagan, Candace D. Carter, Linda O’Connor, Michael O’Rourke, 
Richard A. Scolyer, Graham J. Mann, Christopher W. Schmidt, Adrian Herington, Nicholas 
K. Hayward. A high throughput panel for identifying clinically-relevant mutation profiles in 
melanoma. Molecular Cancer Therapeutics. 2012. 11(4):888-897.   
 
5.1. Relevance to thesis aims 
 
This paper describes the development of a melanoma specific panel (MSP) of mutations 
that can be used for the identification of clinically-relevant mutation profiles in melanoma 
and addresses Aim 4 of the thesis. Recently, there has been significant success in treating 
cancers using molecularly based targeted drug strategies. One example is the use of 
BRAF inhibitor drugs, such as Vemurafenib or GSK2118436, in the treatment of late stage 
or disseminated melanoma. These drugs are specifically designed to antagonise the 
proliferative effect in tumours harbouring BRAF mutations with an amino acid substitution 
of valine at position 600 (V600E, V600K) and have begun to show improvements in overall 
survival rates.  These results have prompted a number of clinical trials using molecularly 
based targeted approaches against alternative mutation events such as Imatinib in KIT 
mutated metastatic melanomas.  
 
Interestingly, the clinical efficacy of molecularly based targeted drugs relies strongly on the 
presence of specific mutations within the patient’s tumour. For example, use of 
Vemurafenib in BRAF wild type tumours can have the opposite effect and promote 
tumorigenesis while mutations both upstream and downstream of BRAF can render the 
drug ineffective. As such, the comprehensive identification of these mutations in a rapid 
fashion is desirable in a clinical setting so that it can inform on choice of modality for 
patient treatment. This report describes a MSP that can quickly assess the profile of 
mutations in tumours that could inform effective treatment regimens for melanoma.  
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A comprehensive literature search and interrogation of the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database was used to generate a list of potential 
mutations to be included in the MSP. After filtering this list using strict criteria, a validation 
stage was performed before a final panel consisting of 46 assays interrogating 39 
mutations in 20 genes was designed. In addition to the development of the MSP, this 
report investigates the occurrence of mutations identified from isolated literature reports in 
a large cohort of samples. This revealed that a number of mutations previously identified 
are either rare or patient specific mutation events; the results of which have important 
implications for future studies utilising next generation sequencing strategies.  Lastly, a 
number of recurrent mutations were identified; reinforcing that these are possible drug 
targets that may be amenable to therapeutic intervention.  
 
5.2. Contribution of the candidate 
 
Project and experimental design was conducted in association with Nick Hayward and 
Darryl Irwin. Design of the validation panel and final MSP was performed in conjunction 
with Darryl Irwin. I performed sample preparation, generated and analysed results from the 
MSP, and drafted the manuscript.   
 
5.3. Acknowledgment of the contribution of others 
 
The panel of C series stage III metastatic melanoma samples were collected by Michael 
O’Rourke and cell lines from these samples were established by Cathy Lanagan, Linda 
O’Connor and Christopher W. Schmidt.  Lauren Aoude contributed to the generation of cell 
line stocks and the subsequent extraction of DNA. An independent series of melanoma 
tumour and cell line DNA was prepared by members of the Melanoma Institute of Australia 
that included Gulietta M. Pupo, Varsha Tembe, Candace D. Carter, Richard A. Scolyer 
and Graham Mann. Darryl Irwin contributed to the design and analysis of the MSP while 
Priscilla Hunt performed independent replication experiments of the panel to assess 
accuracy. All authors reviewed and supplied comments on the final manuscript prior to 
publication.  
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Chapter 6 
 
Discussion 
 
Advances in sequencing technology have changed the approach of cancer genomics in 
the identification of causal genes involved in tumorigenesis.  However, as effective as 
these approaches are, a number of technological limitations still remain. In this section of 
the discussion, these problems are addressed in the following perspectives article: 
 
Ken Dutton-Regester and Nick Hayward. Reviewing the somatic genetics of melanoma: 
from current to future analytical approaches. Pigment Cell and Melanoma Research. 2012. 
25(2):144-54. 
 
This review discusses a number of limitations associated with cancer genomics using 
next-generation sequencing analysis, in particular, the difficulty in identifying ‘driver’ 
mutation events from the background noise of high mutation rates observed in metastatic 
melanoma. Although next generation sequencing can be used to identify a number of 
interesting targets, those that are functionally relevant to the disease are increasingly 
difficult to identify. In order to overcome this, a number of complementary strategies can 
be employed that include transcriptome analysis, functional screens, and the combination 
of multiple high-throughput data sets. In addition, this review discusses areas that have 
currently been neglected such as the significance of mutations within non-coding regions 
of the genome.  
 
In the final conclusion chapter, results from this thesis will be discussed in respect to 
current therapeutic strategies. This includes the putative involvement of TFG in the 
activation of the MAPK pathway, the association of a new apoptotic pathway in the 
development of melanoma through mutation of MAP3K5 and MAP3K9, and the potential 
significance of mTOR inhibition in NF1 mutant BRAF/NRAS WT melanomas.  The 
decreasing costs and ability of next-generation sequencing to rapidly identify putative drug 
targets in tumours is rapidly seeing this technology move from research environments into 
clinical practice. The application of next-generation sequencing in regards to personalised 
medicine will be discussed and describes the remaining hurdles for the establishment of 
this technology for routine clinical practice. 
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Chapter 7 
 
Conclusion 
 
7.1. Future directions of research 
 
The results presented in this thesis identify a number of new mutations and genes involved 
in the development and progression of metastatic melanoma (Figure 7.1). These findings, 
although important in their respective manner, raise a number of questions and research 
directions that warrant further investigation.  
 
7.1.1. The functional significance of mutations of TFG in metastatic melanoma 
 
Chapter 2 describes the identification of a number of putative tumour suppressor genes 
involved in metastatic melanoma, including the mutation of TFG in 5% of melanomas [1]. 
Although mutations within TFG are interesting, experimental evidence is ultimately 
required to determine the role of these mutations in tumorigenesis. 
 
The biological role of TFG has not been extensively investigated; however, TFG has been 
frequently involved in oncogenic fusion events in a variety of cancers [2-5]. During these 
events, the 5’ end of constitutively expressed TFG is fused to the 3’ end of a kinase 
resulting in deregulated signalling activity and increased cell proliferation. Although the 
functional effect of the oncogenic kinase fusion event has been determined, these studies 
have neglected to investigate the significance of the carboxyl deletion or disruption of TFG 
and its potential role in tumorigenesis.  
 
It was previously shown that TFG can activate both the MAPK and NF-κB pathways [6]. In 
regards to the NF-κB pathway, evidence suggests that TFG, through direct binding, is 
involved in the same high molecular weight complex as NEMO, a member of the IκB 
complex [7]. The presence of several motifs within the TFG protein, including the presence 
of a coiled coil domain within the carboxyl end [8], and a Phox and Bem1p (PB1) module 
responsible for protein interactions and cytoplasmic signalling [9], suggests an important 
biological role in the binding of TFG to other proteins. Topical data provided in Chapter 2 
shows a propensity for mutations to occur at the 3’ end of TFG; this combined with 
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Figure 7.1: New genes mutated in melanoma identified in this thesis. Mutations 
were identified in TFG and NF1 and may be responsible for the activation of the MAPK 
pathway. Approximately 25% of melanomas exhibited a mutation in either MAP3K5 or 
MAP3K9 and may represent a novel apoptotic pathway to melanoma development.     
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oncogenic fusions resulting in the disruption of the 3’ end of TFG provides supporting 
evidence that this region of the gene may be functionally important, hypothetically resulting 
in differential interactions with cellular proteins. In relation to the NF-κB pathway, mutation 
of TFG may affect its interaction with NEMO, causing constitutive activation of the pathway 
(Figure 7.2).  
 
To determine the importance of TFG in tumorigenesis, a number of experiments could be 
performed. Firstly, in vitro mutagenesis studies that compare wild-type (WT) TFG to 3’ end 
deleted or point mutated TFG could be used to assess the effect of abrogated protein 
function in a variety of cellular processes including proliferation, invasion and apoptosis. 
The aforementioned putative role of TFG in protein interactions could be assessed by the 
use of co-immunoprecipitation, linked with mass spectrometry analysis or western blot 
analysis. Abrogated function of the 3’ end of TFG may also result in aberrant localisation of 
TFG and protein interactions within the cell; this could be assessed using immuno-
fluorescence experiments. An example of aberrant protein localisation was recently 
demonstrated by increased nuclear expression of BRMS1 in metastatic melanoma 
compared to melanocytes, which contributed to increased cell invasion [10].  
 
Point mutations of TFG were mutually exclusive to NRAS and BRAF mutations in 
metastatic melanoma; this is of relevance to melanomagenesis since this tumour type 
frequently exhibits constitutive activation of the MAPK pathway. As such, it is possible that 
mutation of TFG may represent an alternative mechanism to activation of the MAPK 
pathway. Targeted functional analysis focusing on MAPK activation through BRAF, MEK 
and ERK phosphorylation could be determined through ectopic expression of WT and 
mutant versions of TFG and western blot analysis in cell lines. If mutation resulted in the 
activation of these proteins, confirmation of the functional effect on the cell should be 
tested though a variety of in vitro experiments including proliferation, scratch wound 
closure and gel invasion assays. Appropriate in vivo studies such as tumorigenicity assays 
in mice would provide strong evidence towards an important functional role of TFG in 
melanoma.  
 
Lastly, it is important to note that the overall numbers of melanomas with TFG mutations 
within this study are relatively low. Sequencing of larger cohorts of melanomas, including 
BRAF/NRAS WT or BRAF/NRAS mutant tumours, will be required to determine an 
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Figure 7.2:  Hypothetic model of how mutations within TFG may affect activation of the 
MAPK pathway. Mutation of TFG, particularly the carboxyl-end of the protein, may change its 
interaction with other  proteins. In this example, mutation of TFG results in a structural 
alteration of the IKK complex, leading to over-activation of the NF-κB pathway.  
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accurate frequency of TFG mutation and confirm mutual exclusivity to BRAF/NRAS 
mutation.  
 
7.1.2. The therapeutic relevance of MAP3K5 and MAP3K9 mutation in melanoma. 
 
In chapter 3, inactivating mutations in MAP3K5 or MAP3K9 were identified in 9% and 15% 
of metastatic melanomas, respectively [11]; these mutations may represent a novel 
pathway in the development of melanoma (Figure 7.1). This study was part of a large 
collaboration effort and as such, significant functional analysis was performed to elucidate 
the biological role of MAP3K mutations. Analysis revealed that MAP3K5 and MAP3K9 
mutation affects phosphorylation activity of the proteins, downstream signalling, and may 
contribute to the resistance observed with use of chemotherapy, specifically, the role of 
MAP3K9 mutation in Temozolomide resistance.  
 
Although understanding chemo-resistance in melanoma may improve this therapeutic 
strategy, this approach has recently been superseded by alternative drugs, such as 
Vemurafenib in patients with BRAF mutant tumours [12].  As such, current research has 
focused on understanding the mechanistic action of molecularly-based targeted drugs in 
order to attain effective long lasting responses in patients. Since MAP3K5 and MAP3K9 
have critical roles in the regulation of apoptosis, investigating the effect of mutation in 
these genes in respect to current molecular based drug strategies is warranted. Mutation 
of MAP3K5 and MAP3K9 may result in intrinsic drug resistance to BRAF or MEK 
inhibitors, and thus, could predict the efficacy of such therapeutic strategies, acting as a 
biomarker for the stratification of positive or negative responders. This hypothesis could be 
determined through a retrospective analysis of the prevalence of MAP3K5 and MAP3K9 
mutation between patients who responded, to those who did not respond to therapy.  
 
Mutation of MAP3K5 and MAP3K9 may be amenable to therapeutic intervention; however, 
since the mutations within these genes appear inactivating, this presents a difficulty in 
developing an effective drug strategy. Currently, the majority of drugs that have been 
approved or are under clinical development, are designed to abrogate the effect of 
oncogenic mutations that result in a ‘gain of function’.  In contrast, the re-establishment of 
gene function from inactivating mutations is currently not easily within the realms of 
modern pharmaceutical drug design. However, it is conceivable that intervention through 
targeting of genes upstream or downstream of the identified mutations may result in 
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rational drug. This concept is discussed in more detail in 7.2.4. The identification of targets 
not directly amenable to therapeutic intervention. 
 
7.1.3. The functional and therapeutic significance of NF1 mutation in melanoma.  
 
Whole-exome sequencing strategies in Chapter 4 identified mutually exclusive mutations 
of NF1 in BRAF/NRAS WT melanomas. This finding is particularly exciting as it may 
represent a new therapeutic avenue for this subset of patients; however, significant 
research into the role of NF1 in the development of melanoma still needs to be performed.  
 
Firstly, the frequency of NF1 mutation needs to be determined in a larger subset of 
tumours in both BRAF/NRAS WT and BRAF/NRAS mutant melanomas. Although 
analyses of previously published and unpublished melanoma exomes show that NF1 
mutation is mutually exclusive to BRAF and NRAS mutation, the overall numbers are low. 
As NF1 is a large gene consisting of 57 exons, the use of traditional sequencing 
technology would not be a cost effective approach and would benefit from targeted next-
generation sequencing strategies.  
 
Consistent with a dual-hit inactivation model of tumour suppressor genes, tumours from 
patients with neurofibromatosis, a disease typically associated with abrogated NF1 
function, have both copies of the gene disrupted through a variety of mechanisms.  
Inactivation of NF1 can occur through the introduction of truncating nonsense mutations, 
loss of heterozygosity (LOH) or through RNA editing of the NF1 transcript [13, 14]. Within 
the results presented in Chapter 4, point mutations of NF1 were documented in 
melanoma, of which, all resulted in truncating mutations. Although one patient, C077, had 
two nonsense mutations in NF1, the remaining patients had only one allele affected. 
Further investigation into chromosomal copy number changes, including LOH, as well as 
the possibility of RNA editing should be investigated.  RNA editing is of particular interest, 
as potentially, NF1 may be affected in a larger proportion of BRAF/NRAS WT melanomas 
than first indicated by this study.  
 
After determining the extent and frequency of NF1 mutation in melanoma, the next logical 
step is to focus on the biological role of abrogated NF1 protein function. In Chapter 4, 
clustering expression array analysis suggests that BRAF/NRAS WT melanomas are not 
distinct molecular entities and are likely to have constitutive activation of the MAPK 
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pathway; this needs to be conclusively determined through western blot analysis, 
specifically, through assessment of phosphorylation activity of BRAF, MEK and ERK.  As 
existing literature of NF1 function dictates a significant role in the negative regulation of 
NRAS [15], it would be expected that upon NF1 inactivation, subsequent increased kinase 
activity of downstream members of the MAPK and PI3K pathways would occur.  
 
A recent study identified the reliance of mTOR signalling in NF1 mutant adult acute 
myeloid leukaemias, which were susceptible to mTOR inhibition by rapamycin [16]. This is 
a compelling finding with clinical significance for NF1 mutant BRAF/NRAS WT 
melanomas, a subset of tumours that may be amenable to similar therapeutic intervention. 
mTOR signals downstream of the PI3K pathway; a pathway frequently deregulated in 
melanoma through mutation of NRAS and PTEN. Although early reports investigating the 
downregulation of NF1 in melanoma determined no such reliance of mTOR pathway 
signalling [17], confirmation of these findings should be replicated due to the potential 
impact that this therapeutic avenue would provide for BRAF/NRAS WT melanomas.   
  
 
7.2. Personalised therapeutics- using mutation data within a clinical 
setting  
 
Recent advances in technology have resulted in an inverse relationship between the 
associated costs and output capabilities of next-generation sequencing platforms. With this 
increased capability for the generation of data, it is expected that an avalanche of new 
genes and mutation events contributing to melanomagenesis will be discovered. In the 
previous chapter, the limitations of current sequencing technologies in discerning driver 
mutation events to passenger mutation events were discussed. In contrast, this section will 
describe the applicability of sequencing technology and mutation detection within a clinical 
setting, with particular emphasis on the use of this data in personalised therapeutics.  
 
7.2.1. Molecularly-based targeted therapies 
 
Recent advances in molecularly-based targeted drug strategies have begun to show a 
significant impact on overall survival for patients with metastatic melanoma. Notably, the 
FDA approval of Vemurafenib in August 2011 was a significant milestone for the 
melanoma research community and the field of personalised therapeutics. Furthermore, a 
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number of promising molecular based drug strategies for use in melanoma are currently 
under investigation or on the horizon; this includes the use of Imatinib or Lapatinib in KIT 
or ERBB4 mutant melanomas, respectively [18, 19]. However, a common theme between 
the successful applications of molecularly-based targeted drugs within the clinic, strongly 
relies on the correct stratification of patients based on their tumour mutation profiles, 
essentially guiding drug efficacy and/or resistance.  
 
Oncogenic mutation screens, such as the melanoma-specific mutation panel discussed in 
chapter 5, can be used for the identification of clinically relevant mutation profiles within 
tumours. These oncogenic mutation panels have a number of advantages compared to 
alternative methodology platforms and benefit from minimal sample requirements, cost 
efficacy, and high throughput analysis. The latter is of significance for the successful 
application of mutation detection within the clinic; delays in implementing treatment 
regimens can be a critical factor determining patient survival, in particular, for those who 
have aggressive late stage or disseminated disease.  
 
One consideration that has yet to be comprehensively explored is inter- and intra-
heterogeneity of tumour specimens within a patient. This includes differences between the 
mutational evolution of primary to metastatic tumour sites, variability between multiple 
metastatic deposits throughout the body, or the spectrum of mutations or subclones 
present within a given tumour. This was recently addressed through a comprehensive 
genomic analysis of multiple deposits and tumour sections from biopsies of several 
patients with renal carcinoma [20]. Interestingly, significant intra-tumour heterogeneity was 
observed; 63-69% of all somatic variations were not detectable across all tumours and 
frequent mutant allelic imbalances were observed between tumours. Two main clinical 
implications arise with the observation of patient tumour heterogeneity. Firstly, singular 
biopsy analysis, as is routinely performed within the clinic, may be insufficient for 
estimating the entire spectrum of mutations within a tumour. Secondly, tumour 
heterogeneity may result in inaccurate diagnoses of effective treatment strategies using 
molecularly-based drugs. Thus, the unique capabilities of mutation screening panels would 
allow easy and cost effective analysis of multiple, spatially separated biopsies within a 
single tumour, and or, testing multiple metastatic deposits.  
 
Despite the advantages, mutation screening panels such as the melanoma-specific 
mutation panel [21] are limited by their ability to only assess ‘oncogenic’ or single 
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nucleotide mutation events. Tumorigenesis is a complex interaction of genetic 
abnormalities contributing to the neoplastic process involving activating oncogenic 
mutations in combination with inactivating tumour suppressor mutations. The latter, due to 
the propensity of mutations to occur throughout the entire length of the gene, essentially 
relies on the use of sequencing technology for the successful identification of all genetic 
mutations. As such, the use of next-generation sequencing will likely be a desirable 
platform to comprehensively assess mutation profiles. Indeed, specialist oncology clinics 
have already implemented routine next-generation sequencing platforms to ascertain 
therapeutically relevant mutations within individual patient tumours in order to personalise 
treatments [22].  
 
Although the promise of next-generation sequencing within the clinic seems achievable 
with existing technology, a number of technical limitations have yet to be solved before it is 
likely to be widely adopted by oncology clinics (reviewed in more detail [23, 24]). Of utmost 
importance to the implementation of any methodology within the clinic, not just concerning 
the concept of next-generation sequencing, is accuracy.  
 
The clinical laboratory improvement amendments (CLIA) certification (or its equivalent) is a 
regulatory standard to which all clinical laboratory testing must be adhere. Within these 
guidelines, strict adherence to set protocols is required to uphold consistent accuracy, 
reliability and timeliness of test results. This is highly significant in a clinical diagnostic 
cancer setting, as patient survival and prognosis is intimately associated with the rapid 
adoption of efficacious treatment strategies. Thus, any technology used within this arena 
will require high accuracy with low rates of false positive and false negative calls. This is 
problematic for current next-generation sequencing platforms where high-throughput, 
which is desirable in a research setting, offsets the rate of accuracy. Although excessive 
coverage increases the rate of accuracy, this in itself poses a number of issues, 
particularly the additional cost and associated bioinformatic processing time. Platform 
specific biases must be also considered and is why, if possible, combinations of 
technologies can significantly improve data quality and output.  
 
Reliability is another critical issue of concern for the implementation of next-generation 
sequencing platforms. As stated above, strict adherence to protocols is required in order to 
maintain accuracy and consistency. Due to the rapidly progressive nature of sequencing 
technology, upgrades to machines or improvements to sequencing chemistry are 
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consistently being released to increase data output and reduce sequencing costs, 
sometimes at bi-annual frequency. This is problematic in a CLIA setting due to the 
investment of time and expenses required for the establishment of standardised workflows 
and procedures. Other technical considerations include the adoption of automated library 
preparation to reduce labour intensive procedures and to improve reliability, the 
standardisation of bioinformatic analysis methods, and the current need for independent 
platform validation of identified mutations.   
 
These concerns aside, another debate currently exists into what sequencing depth or 
coverage should be required for use in a clinical setting, specifically, whether to analyse 
patient samples with whole-genome, exome, or targeted gene sequencing strategies.  
Regardless, it must be noted that in relation to acquired drug resistance using existing 
molecular based targeted therapies, genetic testing alone will be insufficient to 
comprehensively determine all mechanisms of resistance. For example, Vemurafenib 
resistance in BRAF mutant melanomas include acquired mutations in MEK and NRAS, 
differential splicing and amplification of BRAF and up-regulation of tyrosine kinases such 
as PDGFRA and COT1 [25-30]. Determining these mechanisms will require multiple 
platform analysis, and in regards to the latter, non-genetic analytical approaches. Although 
it is hard to make conclusive predictions due to the regular and rapid advances in the 
sequencing industry, it is unlikely that widespread adoption of next-generation sequencing 
within the clinic will occur for at least another 5 years. However, during these interim years, 
analysis will most likely concentrate on the identification of mutations with known clinical 
significance to existing molecularly-based targeted drug strategies.  
 
7.2.2. Immunological approaches. 
 
Alongside the recent success of molecularly-based targeted drugs such as Vemurafenib 
[31], and CTLA4 inhibition strategies with Ipilimumab [32], a number of alternative 
strategies are currently being investigated. One approach that is showing promising results 
in patients with metastatic melanoma is adoptive cell therapy (ACT) with use of tumour 
infiltrating lymphocytes (TIL) [33]. This strategy involves autologous TIL isolation and 
cultivation in vitro with IL2, selection of tumour reactive cultures in matched tumour cell 
lines, then systemic re-introduction of cultured reactive TILs [34]. Patients will also typically 
undergo lymphodepletion regimens during cell preparation as this method results in long 
lasting responses [35]. Using this therapeutic approach, complete responses in 20 of 93 
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(22%) metastatic melanoma patients  were observed, 19 patients of which were alive 3 
years post-treatment [36].  
 
Despite these impressive results, a number of limitations to the method have been outlined 
and it is recognised that TIL therapy will only be effective for 50% of all melanoma patients 
[36]. Limitations include the requirement of clinical resection of tumour nodules of at least 
2 cm in diameter in order to obtain sufficient TIL, and the subsequent isolation of sufficient 
tumour reactive lymphocytes. Recently, the efficacy of ACT acquiring TILs using 
ultrasound-guided needle biopsy in 11 patients was performed; although this was a small 
cohort, 4 patients demonstrated objective clinical responses, highlighting the efficacy of 
this less invasive, less expensive approach [37]. However, the true clinical benefit of this 
technique needs to be determined though testing in a larger cohort of patients, and, as 
mentioned previously, the significance of inter-tumour heterogeneity may need to be 
determined for this specific application [20]. 
 
A promising alternative that circumvents the need for cultivation of TILs from a dissected 
tumour mass is the genetic engineering of peripheral blood lymphocytes [38]. This strategy 
can also overcome the difficulty of identifying tumour reactive TILs and involves the 
manipulation of blood lymphocytes to react to specific antigens presented within the 
tumour. A seminal paper released in 2006 by Morgan et al., engineered peripheral blood 
lymphocytes to recognise MAGE-1, a melanoma differentiation antigen, in order to 
replicate immunogenicity with autologous TILs [38].  Although the response rate with 
modified blood lymphocytes (2 of 15 patients or 13%) did not achieve the same level of 
efficacy as the autologous TIL approach (approximately 50%), further research efforts into 
improvements of the technique may reduce the disparity between these methods. 
 
The promising results of ACT with TILs may benefit from concurrent use of next-
generation sequencing technologies within the clinic. It has previously been shown that 
single point mutations within genes can act as epitopes, such as NRAS Q61R in 
melanoma [39], and elicit strong immunogenic responses in cancer patients. As such, it 
may be possible to harness the comprehensive identification of mutations in tumours from 
sequencing technologies to develop highly specific, individualised, engineered TILs from a 
cocktail of mutation epitopes (reviewed in more detail [40]). 
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A number of reports have begun to determine the efficacy and details of such an 
approach; this includes a recent comprehensive investigation of the T cell antigen 
specificity in human melanoma [41]. In this approach, a comprehensive compilation of all 
known melanoma-associated antigens were compiled and tested for immunogenicity 
against 63 TIL cultures from 19 patients. A total of 175 tumour associated antigens that 
included mutated and over-expressed antigens as well as those involved in differentiation 
and cancer-testis/onco-foetal origin, resulted in 90 responses against 18 epitopes. 
Notably, the majority of the responses derived from differentiation antigens and not from 
mutant epitopes; however, the authors failed to assess the mutation status of the tumours 
from which the TILs were isolated and this may explain the lack of response with this class 
of antigen.  
 
Building on this finding, Castle et al. assessed the mutanome of B16F10 murine 
melanoma cells for its ability to result in an immunogenic response, specifically, in the 
context of establishing a multi-epitope tumour vaccine [42]. Next-generation sequencing 
revealed a total of 962 non-synonymous single point mutations, of which, 563 were within 
genes that were highly expressed. Immunization of mice with long peptides containing 50 
of the validated mutations resulted in one third eliciting in vivo immunogenic responses (16 
of 50); furthermore, 60% of the immunogenic responders showed preferential sensitivity of 
mutant epitope compared to wild-type sequence. In addition, in vivo mutant peptide 
immunization conferred tumour control, indicating the efficacy of single amino acid 
alterations as epitopes in a therapeutic vaccine setting.  
 
These results provide a proof of principle for the potential application of personalised 
molecularly-engineered TILs that are specific to an individual’s tumour mutation profile. 
However, the application of this strategy has some important considerations and 
limitations. Firstly, the technology in regards to sequencing and the identification of mutant 
epitopes eliciting an immune response is currently time consuming and laborious; 
however, the improvement of sequencing technologies and bioinformatic analyses should 
reduce the impact of this process. One interesting possibility is the curation of a database 
containing documented immunogenicity mutant epitopes, observed experimentally or 
within the clinic, for the rapid identification of targets for therapeutic design. This is 
exemplified in the aforementioned study where ACTN4, a previously identified epitope 
[43], was replicated in the mutanome study of B16F10 [42]. Another potential limitation is 
the loss of expression or clonal selection of mutant epitopes within the tumour, including 
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evolution selection pressures induced during the course of therapy. Multi-epitope 
therapeutic design has the potential to overcome this problem, however this approach 
requires further investigation. 
 
One potential advantage for personalised TIL therapy is that discerning the difference 
between driver and passenger nonsynonymous mutations should not be necessary as 
both can elicit immunogenic reactions. This was demonstrated in the B16F10 mutanome 
study where one of the strongest reactions specific to a mutant epitope was a K739N 
mutation in KIF18B; this mutation does not localise to any functional or conserved domain 
and most likely represents a passenger mutation event [42]. If so, this shows promise for 
immunological therapeutic design as this expands the potential pool of mutant epitopes 
available; even more so for melanoma where the intrinsic rates of mutation are 
considerably higher than other cancers due to carcinogenic exposure of solar UVR. 
 
Expanding the suite of treatments available for metastatic melanoma will act positively on 
rates of overall survival and help overcome issues of therapeutic resistance or tumour 
remission; any therapy that shows an improvement in overall survival or clinical activity will 
warrant further investigation. As TIL therapy has already demonstrated robust responses 
on patients who have undergone multiple refractive therapeutic treatments, including 
dacarbazine and Ipilimumab [36], first line treatment regimens concurrent with TIL 
preparation may be an effective strategy for improving overall survival. In this case, if the 
first line of treatment fails, TIL therapy can be administered rapidly as strong immunogenic 
personalised TILs will by then have been established; however, this would be at 
considerable expense but may represent an effective short term strategy until robust drug 
combination strategies are discovered. The combination of individualised TIL therapy 
through the identification of tumour specific epitopes using next generation sequencing is 
an exciting prospect for future treatment of patients with metastatic melanoma, however, 
this approach requires further research.       
 
7.2.3. Diagnostic and biomarker applications. 
 
Next-generation sequencing technology has demonstrated value in personalised 
biomarker identification for the clinical management of patients [44]. This study utilised 
massively-parallel sequencing to identify chromosomal translocation events in a method 
called 'personalized analysis of rearranged ends' or PARE. In this process, fusion events 
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in solid cancers were initially identified using PARE, before sensitive digital PCR assays 
were designed to detect these rearrangements from circulating DNA in patient plasma 
samples.  This approach was highly sensitive, and able to detect re-arrangements at a 
frequency of 0.001% in sample material also containing normal DNA.    
 
The application of PARE in a series of plasma samples taken throughout the course of a 
patient’s therapy highlighted the potential benefits of this approach in a clinical setting [44]. 
Levels of the identified re-arrangement detected in circulating DNA from plasma showed a 
significant decrease after primary resection, an increase after metastatic dissemination, 
and a decrease after the commencement of chemotherapy; effectively, levels of the 
detected re-arrangement in plasma closely followed the tumour burden within the patient. 
As such, PARE could provide an effective and highly sensitive method to determine 
disease progression following treatment. In the assessment of tumour acquired drug 
resistance, PARE may detect patient relapse more rapidly than conventional approaches 
such as computed tomography (CT) scans, however, this has yet to be determined.  
 
Reciprocal to the potential of personalised TIL therapy, the need for discerning driver and 
passenger translocations is largely negligible; the only requirement is retained tumour 
expression of the fusion gene throughout the course of treatment. It is interesting to 
speculate whether point mutations identified through next-generation sequencing may act 
as superior biomarkers to PARE. Although single base mutations can appear artefactually 
through the introduction of errors via PCR, simultaneous analysis of multiple mutation 
events within the tumour may increase accuracy while circumventing the issue of clonal 
selection or heterogeneity within the tumour.  Further research into the application of next-
generation sequencing in biomarker identification may have considerable significance for 
managing patient therapy within the clinic. 
 
7.2.4. The identification of targets not directly amenable to therapeutic intervention  
 
The rate of mutation in melanoma is high; although the majority of these mutations 
represent passenger events, it is still undetermined how many driver mutations are 
required for melanomagenesis.  A proportion of non-synonymous mutations in genes, such 
as BRAF V600E, are amenable to therapeutic intervention through the design of mutation 
specific inhibitor strategies, or via high throughput chemical drug screens. However, it has 
been suggested that in regards to the ‘druggability’ of proteins within the human genome, 
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only ~10% of genes can be targeted effectively with traditional pharmaceutical drug design 
[45, 46]. As such, a large number of mutations identified from large scale cancer genomic 
studies, even if responsible for driving tumorigenesis, will not be able to be therapeutically 
targeted directly. This raises an important issue for the application of personalised 
molecularly-based medicine in a clinical setting, particularly for the subset of patients 
whose mutation profile does not present with druggable targets.  
 
One strategy to address the abovementioned problems is the use of pathway analysis and 
requires an understanding of the functional role that mutations play within signalling 
networks. In this sense, it is theoretically possible to achieve therapeutic success by 
targeting genes upstream or downstream of the mutant gene in question. An example of 
this approach has recently been suggested with the inhibition of ERK1/ERK2, proteins 
downstream of BRAF and MEK in the MAPK pathway, through the use of shRNA [47]. 
Although for 50% of melanoma patients, the MAPK pathway can be targeted through use 
of BRAF inhibitors, due primarily to the presence of BRAF V600E mutations, patients with 
NRAS mutations, or who are BRAF/NRAS WT, are currently refractive to this therapeutic 
approach despite constitutive activation of the MAPK pathway. In vitro inhibition of 
ERK1/ERK2 in BRAF mutant A375 melanoma cells was more effective at promoting 
apoptosis than BRAF inhibitors, such as PLX4032 [47].   Although the effect of 
ERK1/ERK2 inhibition on BRAF WT melanomas was not assessed, this approach may be 
an effective strategy in this subset of melanoma patients.  
 
Despite the ability to target downstream or upstream members of biological pathways in an 
experimental in vitro setting, a number of issues are raised when this concept is 
considered in an in vivo clinical setting. One approach that has gathered significant 
interest since their identification is the use of siRNA knockdown strategies to inhibit 
overactive protein activity, or signalling networks.  Although siRNA strategies are effective 
in vitro cell culture experiments, delivery of the siRNA becomes difficult in vivo as current 
approaches are ineffective. However, significant research in improving the delivery is 
currently underway and is beginning to demonstrate clinically actionable results in 
melanoma [48, 49]. It will be interesting to see how the applications that pathway analysis 
and inhibitor based strategies will affect treatment strategies within the future; however, an 
extensive understanding in the biology of the targeted pathways will be required before 
success with these approaches is achieved. 
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7.3. Concluding statement 
 
Melanoma is an aggressive cancer that accounts for nearly all skin cancer related 
mortality; this is largely due to late stage or disseminated melanoma, which historically, 
has been refractive to traditional chemotherapeutic strategies. However, recent success 
with molecularly-based targeted drugs in metastatic melanoma, such as Vemurafenib in 
patients with BRAF V600E mutations, have begun to demonstrate an improvement in 
overall survival and supports the use of ‘personalised medicine’ within the clinic. Thus, 
understanding the genetic mechanisms of metastatic melanoma will ultimately lead to the 
development of novel drug strategies, while also improving existing therapeutic 
approaches in treating this disease.  
  
In this thesis, a comprehensive analytical approach has been used to determine the 
genetic mechanisms of tumorigenesis in a panel of stage III local lymph node metastatic 
melanomas. Using high-throughput technologies, including whole-exome sequencing 
strategies, a number of novel genes involved in the development of metastatic melanoma 
were discovered. This includes the identification a putative tumour suppressor gene TFG 
that is mutated in 5% of melanomas and may activate the MAPK and NF-KB pathways 
(Chapter 2); the identification of MAP3K5 and MAP3K9 mutations in 25% of melanomas 
involved in cell regulated apoptosis (Chapter 3); and the identification of inactivating 
mutations of NF1 in BRAF/NRAS WT melanomas, which may be susceptible to 
therapeutic intervention through mTOR inhibition using rapamycin (Chapter 4). 
 
As the numbers of mutation events contributing to melanomagenesis are increasingly 
identified and their subsequent significance to current or novel drug strategies determined, 
the utilisation of this information will progressively move from a research setting towards 
routine clinical applications. For instance, the development of a melanoma specific 
mutation panel, as described in this thesis (Chapter 5), is one such example of how 
genetic information could be used to guide efficacious treatment strategies with 
molecularly-based targeted drugs. However, a number of ethical issues and technical 
considerations will need to be discussed before the use of mutation screening panels or 
next generation sequencing platforms can be implemented into routine use within 
oncology clinics. This aside, a number of specialist clinics are currently embracing this 
technology and no doubt, will contribute to the development of the standardised practices 
required for the widespread adoption of this technology.  
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 The advance in sequencing technology over the last decade has without a doubt, changed 
the approach to cancer genetic research. Consequently, this is an exciting time for both 
researcher and patient alike, as the adoption of this technology is increasing our 
understanding of the genetic mechanisms of melanoma development, and as such, will 
hopefully lead to the improvement of therapeutic outcomes for patients with this disease.  
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Appendix 
 
C Series Patient Selection Criteria 
 
Inclusion Criteria: 
 
Prior to surgery, where possible and again one week prior to the first vaccination, the 
patient must fulfil the following criteria: 
 
1. Histologically confirmed Melanoma of Stage III as determined by tissue sample 
obtained during surgery 
2. ECOG Performance status of 0  
3. Normal Haematological parameters 
4. Acceptable Liver and Renal function parameters  
5. Negative serology for HIV, Hepatitis B and Hepatitis C 
6. Willingness to sign and ability to understand an informed consent form. (Both the 
Patient and parent/guardian for those under 18 years of age.) 
 
Exclusion Criteria: 
 
Patients with any of the following will be excluded from enrolment in this study: 
 
1. Autoimmune Disease or use of immune-suppressive therapy (oral or systemic 
corticosteroids) 
2. Prior chemotherapy or immunotherapy 
3. Prior gene therapy, vaccine therapy or cytokine therapy 
4. Post-operative complications requiring ongoing medical care that would 
preclude experimental vaccine therapy. 
5. Post-surgical local radiation therapy 
6. Unsuccessful vaccine preparation (for example, insufficient tumour cells) 
7. Clinically significant active infection 
8. Uncontrolled systemic disease or medical problems that would preclude 
surgery or participation in this study (ie. neurological, cardiovascular, 
endocrine) 
9. History of other malignancies, except for adequately treated and controlled non-
melanomatic skin cancer or in situ cervical cancer 
10. Participation in other investigational new drug trial within 30 days of surgery 
11. Pregnancy 
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